cancer therapy & research center (ctrc) annual report 2015

C A N C E R T H E R A P Y & R E S E A R C H C E N T E R

2 0 1 5 A N N U A L R E P O R T

Cancer Therapy & Research Center n Annual Report 2015 n 2

OUR MISSION

The mission of the CTRC is to reduce the cancer burden in South Texas through the highest quality

cancer care; groundbreaking research aimed at reducing the incidence and mortality of cancer;

education of future cancer scientists and clinicians; and cancer prevention programs focused

on our unique population.

DIRECTOR Ian M. Thompson Jr., M.D.

DEPUTY DIRECTOR Tim H. M. Huang, Ph.D.

CONTRIBUTING WRITERS Elizabeth Allen

Tyler Curiel, M.D. Natalie A. Gutierrez, M.A.

Mary Jackson Woondong Jeong, M.D.

Anand Karnad, M.D. Kate Lathrop, M.D.

Lori Moctezuma Sheri Ortiz

Babatunde Oyajobi, M.D., Ph.D. Susan Padalecki, Ph.D.

Will Samson, M.J. Steve Weitman, M.D., Ph.D.

MANAGING EDITOR Natalie A. Gutierrez, M.A.

DESIGN & PRODUCTION Kris Enders Doyle

PRINTING UT Print

Photos provided by Noell Vidaurri, Creative Media Services/Institutional Marketing, and Lester Rosebrock

7979 Wurzbach Rd. San Antonio, TX 78229

210-450-1000

www.ctrc.net

THE BUTTERFLY EFFECT AND THE CTRC

Coined by late American mathematician Dr. Edward Norton Lorenz, the Butterfly Effect theory holds that even the smallest occurrence

can change the course of the universe forever.

Lorenz likened the “effect” to aspects of a hurricane, as it is influenced by minor weather disturbances,

to the flapping wings of a butterfly. Even movements from the tiny wings can contribute to a major storm

on the other side of the world.

Similarly, at the CTRC, scientists and clinicians dedicate their life’s work to developing

new therapies and cures for all forms of cancers. This passion takes myriad steps,

meticulous hours and oftentimes decades to decipher.

But when their work yields the next great discovery, the result can change the course

of cancer treatment and care with the potential to save lives

across the world for generations to come.

This diagram illustrates Lorenz’ (1917 – 2008)

Butterfly Effect.

http://www.uthscsa.edu/patient-care/ctrc?utm_source=ctrcnet&utm_medium=pageredirect&utm_campaign=ctrcnethomepage

5 GREETINGS

IanM.ThompsonJr.,M.D.__________________________5WilliamL.Henrich,M.D.____________________________6FranciscoGonzález-Scarano,M.D.____________________6CTRCTeam_______________________________________7

6 CTRC BY THE NUMBERS

CTRCFunding______________________________________ 8

9 PATIENT CARE

PatientInspiresCancerTeamstoWinBattle ______________________10TransformedfromHopelesstoHealing___________________________12GeneTherapyDoublesSurvivalinRecurrentGlioblastoma __________14

15 RESEARCH

SpotlightonDonnaAnkerst,Ph.D.__________________________ 16DiscoveryoftheYear_____________________________________ 17ClinicalInvestigatoroftheYear ____________________________ 17ImmunotherapyforElderlyCancerPatients__________________ 18DentistDelvesintoCancerResearch________________________ 19CollaborationandResearchAdvanceBladderCancerTreatment___ 20Double-time______________________________________________ 22Dr.AuneAddressesWorldHealthOrganization ________________ 23

24CLINICAL TRIALS

PassiontoHeal___________________________________25WhatIsaClinicalTrial____________________________ 26

34 EDUCATION AND TRAINING

CultivatingCuriosityinCancerResearch_____________35 PartnershipProducesBioinformaticsDataPros ______ 36 $1.4MillionfromNCIHelpsTrainResearchers_______ 36 Cutting-edgeTraining_____________________________37 PrototypeforProgress ____________________________37

28 SERVICE AND OUTREACH

ResearchersGiveResourcestoSouthTexans_________ 29LupitaMartinez _________________________________ 30Broadband!______________________________________ 31WhatDoestheCTRCMeantoYou?_________________32

38 COMMUNITY IMPACT

BowenBlazesTrailforCTRC’sFuture ________________________ 39ChampionsofEducation,ResearchandCare__________________ 40GreetingsfromtheCTRCBoardofGovernors_________________ 42CTRCBoardofGovernors_________________________________ 43GreetingsfromtheCTRCFoundation________________________ 44GreetingsfromtheCTRCCouncil___________________________ 44MajorGiftHighlights______________________________________ 45OurDonors______________________________________________ 49

About the coverTheimagesingreenandblueareactualcancercellsseeninhighmagnification.Thegreenfilament-likestructuresaremicrotubulesandaretherailroadsystemofthecells.ResearchersattheCTRCarediscoveringnewdrugsthatdisruptthesestructuresandarestudyinghowinhibitingthefunctionofthesestructuresleadstoanticancereffects.ThebutterfliesintegratedasdesignelementsrepresenttheButterflyEffectoftheCTRCandhowitiscreatingpositiveoutcomesforpatientsandtheirfamilies.Onesmalldifference–whetherincancerresearch,educationorpatientcare–canchangetheuniverse.

Cell image, courtesy of Susan Mooberry, Ph.D.

Expressions of hope give us wingsThispastfallweplacednotecardsandpensatvarioussitesthroughoutourCTRCfacility,askingourpatientstoanonymouslywriteandleaveananswertothequestion“WhatdoestheCTRCmeantoyou?”

Whattheyleftuswasagiftfargreaterthanwecouldeverhaveimagined.Theirsentimentstouchedourheartsandfilleduswithsomuchpridethatwefeltcompelledtosharethemwithyou.

Thatiswhyyouwillfindthese“expressionsofhope”—writtenbyourpatients,staff,facultyandfriends—sprinkledthroughoutthefollowingpages.Onpage32,youwillalsofindawordcloudwedesignedwiththem.

Youwillalsonoticethemotifofbutterfliesthatgracesseveralpages.TheseimagesweretakenfromacollectionofphotographsdonatedtotheCTRCbyoneofourtalentedpatientswhorequestedtoremainanonymous.

Together,thesegiftsgiveuswingstoadvanceinourcriticalmission.TheyserveasremindersofwhyourCTRCissovitaltoourcommunity,andasinspirationtocontinueperseveringtoeliminatecancerforallthosediagnosedandtheirfamilies.

5 n Cancer Therapy & Research Center n Annual Report 2015

IAN M. THOMPSON JR., M.D.DIRECTOR, CANCER THERAPY & RESEARCH CENTER

Mays Family Foundation Distinguished University Presidential Chair for the Director of the CTRC Glenda & Gary Woods Endowed Chair in GU OncologyDoctors Hospital at Renaissance Distinguished University Chair in Urology

AMESSAGEFROMTHEDIRECTOR It is one of the highlights of the year to send my greetings to you on the occasion of the release of the Cancer Therapy & Research Center’s (CTRC) 2015 Annual Report, celebrating 41 years of service to San Antonio, South Texas and to patients around the world who are experiencing or may face a cancer diagnosis.

On the following pages, you will see a constant theme: an urgent desire of CTRC scientists, physicians, nurses, pharmacists, technicians and staff to radically change how we approach cancer through prevention, detection and treatment.

Our scientific teams toil through the night (and you will meet some of them in these pages), truly burning the midnight oil, in search of new ways to target and kill cancer cells. Our groups of physicians, from of as many as 10 different specialties, often assume the responsibility for patients for whom no other treatment is available. These doctors take the discoveries of our scientists and move them into the clinic where lives are changed. Equally important, our entire staff focuses on an overarching responsibility: to treat our patients just as we would like to be treated. Indeed, as I write this letter today, I had two patients who spontaneously sought me out to express their thanks for the extraordinary and personal level of care provided to them by every staff member and health care provider they saw at the CTRC.

The enterprise that is the CTRC – scientific discovery, clinical trials, clinical care by teams of physicians, Texas-wide efforts to prevent cancer, and educating the next generation who will be the Nobel Laureates of the future or may be your or my personal physician – is very resource-intensive.

Throughout this publication, you will see the names of so many people who share our vision of a cancer-free future. This legion of remarkable folks add to the generous friends who, for more than four decades, have laid the foundation for these discoveries and compassionate care. We are grateful to those who have made this possible.

As you read on, please consider, as if they were a member of your own family, the scores of people today who are cared for by our physicians, nurses and staff. Please also remember those scientists, isolated, late into the night, away from their families, seeking the cancer cure of tomorrow. For all of them, it is an urgent passion to work for you and your loved ones.

We are very grateful for your generosity and support that makes this possible.

Sincerely,

Ian M. Thompson Jr., M.D.

(Photo left) Putting their heads together – Ian M. Thompson Jr., M.D., director of the CTRC (right), and Carlos Bermejo, M.D., a former urologic oncology fellow, team up in the operating room. Photo courtesy of the San Antonio Express-News.


GREETINGSFROMTHEPRESIDENT At The University of Texas Health Science Center at San Antonio, we take great pride in the progress of our institution’s National Cancer Institute (NCI)-designated cancer center – The Cancer Therapy & Research Center (CTRC). NCI cancer centers such as the CTRC form the backbone of the nation’s effort to understand the complex biology of cancer and to develop new therapies, which are effective and lead to cures. For that reason, our NCI designation is a point of great pride to each one of us in San Antonio and South Texas.

As the region’s only NCI cancer center and one of only four in Texas with this elite designation, the CTRC is fittingly defined by a steadfast spirit of discovery and innovation. You will see this in the stories in this report. The CTRC’s excellent team, which includes physicians, nurses, health professionals and research scientists, delivers superb care to patients with cancer while searching for new preventions, treatments and cures for this disease. Our patients and their families are the inspiration for our work.

On behalf of each of these families, we thank those in the community who have given to the CTRC so generously to advance this endeavor. Each donation provides the CTRC with resources needed to recruit and retain outstanding faculty, offer an increased number of clinical research studies to patients and their families, expand survivorship services and much more.

In sum, the CTRC is an asset of inestimable value to San Antonio and to our university. It is also our collective pledge to continue the effort to defeat and cure cancer so that our tomorrows dawn more brightly than today.

WILLIAM L. HENRICH, M.D., MACPPRESIDENT, UT HEALTH SCIENCE CENTER SAN ANTONIO

Professor of Medicine

FRANCISCO GONZÁLEZ-SCARANO, M.D.DEAN, SCHOOL OF MEDICINE UT HEALTH SCIENCE CENTER SAN ANTONIO

Vice President for Medical AffairsJohn P. Howe, III, M.D., Distinguished Chair in Health Policy Professor of Neurology

GREETINGSFROMTHEDEAN I am pleased to join Dr. Ian Thompson in greeting you as you receive the 2015 Annual Report of the CTRC. Throughout its history, the CTRC has provided outstanding cancer care to South Texas, and contributed to the improvement in cancer care in the world through its exceptional research programs. One of 69 National Cancer Institute-designated cancer centers in the country (only 62 of these have a clinical component), the CTRC is a jewel in San Antonio medicine.

This year we have further integrated the CTRC into UT Medicine San Antonio, the clinical practice of the UT School of Medicine at San Antonio. This leads to a better patient experience, with smoother transitions between non-cancer care and cancer treatment, and with more efficient centralized procedures. We will continue this effort in the coming year as well.

This is an exciting time for the CTRC – looking back over 41 years of cancer treatments and advances – we can say with pride that we have been, and will continue to contribute many important answers about cancer for individuals being treated here in South Texas, as well as all over the world. I offer not just my congratulations for all they have accomplished, but also my deep gratitude for their hard work that benefits so many.


Susan Padalecki, Ph.D.Associate Director Research Administration

Tom Slaga, Ph.D.Cancer Development and Progression Program Co-leader

Tim H. M. Huang, Ph.D.Deputy Director

Amelie Ramirez, Dr. P.H.Associate Director Cancer Prevention & Health Disparities

Susan Mooberry, Ph.D.Experimental and Developmental Therapeutics Program Co-leader

Karen Block, Ph.D.Associate Director Shared Resources

Luzhe Sun, Ph.D.Associate DirectorTranslational Research

Andrew Brenner, M.D., Ph.D.Experimental and Developmental Therapeutics Program Co-leader

Virginia Kaklamani, M.D., D.Sc.Associate Director Clinical Research

Rong Li, Ph.D.Cancer Development and Progression Program Co-leader

Michael Wargovich, Ph.D.Cancer Prevention and Population Science Program Co-leader

CTRC TEAM

Pratap Kumar, Ph.D.Cancer Prevention and Population Science Program Co-leader

Peter Houghton, Ph.D.Director, Greehey Children’s Cancer Research InstitutePatty McCarrollSenior Director, Finance and AdministrationAnand Karnad, M.D.Chief, Division of Hematology/ OncologyGail Tomlinson, M.D., Ph.D.Chief, Division of Pediatric Hematology/OncologyDonald YorkSenior Director, Information Technology ServicesDeborah IvyDirector, Patient Financial ServicesIvan Reveles, Pharm.D.Pharmacy SupervisorDenise HicksDirector, LaboratorySheri OrtizSenior Director, DevelopmentCynthia SmithDirector, Financial OperationsMelissa NashawatiDirector, Quality Assurance DivisionSusan JohnsonDirector, Clinical Trials OfficeRichard MarkowDirector, SABCS Robin Leach, Ph.D.Chair, CTRC Education CommitteeLaura Gonzales, BSN, RNClinic Manager

SHARED RESOURCESBIOSTATISTICS Director Jonathan Gelfond, M.D., Ph.D.Co-Director Joel Michalek, Ph.D.FLOW CYTOMETRYDirector Benjamin Daniel, Ph.D.Scientific Advisor Vivienne Rebel, M.D., Ph.D.Technical Director Karla GorenaGENOMICSDirector Robin Leach, Ph.D.Co-Director Teresa Johnson-Pais, Ph.D.Research Associate Mandy Hinojosa

MACROMOLECULAR STRUCTURE & INTERACTIONSDirector, MSISR, NMR Dmitri Ivanov, Ph.D.Co-Director, X-ray P. John Hart, Ph.D.Co-Director, MMI Eileen Lafer, Ph.D.Technical Director, NMR Kristen Cano, Ph.D.Technical Director, X-ray Alex Taylor, Ph.D.Technical Director, MMI Virgil Schirf, M.S.

MASS SPECTROMETRYDirector Susan Weintraub, Ph.D.Technical Director, Metabolomics Xiaoli Gao, Ph.D.Research Core Facility Technologist-Sr. Sam PardoResearch Core Facility Technologist Dana MolleurNEXT GENERATION SEQUENCING AND BIOINFORMATICSCo-Director, Sequencing Zhao Lai, Ph.D.Co-Director, Bioinformatics Yidong Chen, Ph.D.Technical Director, Sequencing Dawn Garcia, M.S.

OPTICAL IMAGINGDirector James Lechleiter, Ph.D.Co-Director Exing Wang, Ph.D.Imaging Technologist Jimmy Wewer

MULTIDISCIPLINARY CLINIC LEADERSVirginia Kaklamani, M.D., D.Sc. Breast CenterJohn Sarantopoulos, M.D. Cutaneous OncologyDevalingam Mahalingam, M.D., Ph.D. Gastrointestinal OncologyRobert Svatek, M.D. Genitourinary OncologyTyler Curiel, M.D., Ph.D. Gynecologic OncologyWoondong Jeong, M.D. Head & Neck OncologyAnand Karnad, M.D. Hematologic MalignanciesAndrew Brenner, M.D., Ph.D. Neuro-Oncology

Anne-Marie Langevin, M.D. Pediatric Hematology/OncologyJohn Sarantopoulos, M.D. Phase 1 Oncology Anand Karnad, M.D. Sarcoma Laura Tenner, M.D. Special PopulationsWoondong Jeong, M.D. Thoracic Oncology

DEPARTMENTAL LEADERSHIPPam Otto, M.D.Professor and Chairman, RadiologyJohn H. Calhoon, M.D.Professor and Chairman, Cardiothoracic SurgeryGlenn W. W. Gross, M.D.Professor and Interim Chairman, MedicineChief, Division of Gastroenterology & NutritionIsmail Jatoi, M.D., Ph.D. Professor and Chief, Surgical Oncology & Endocrine SurgeryChul S. Ha, M.D.Professor and Chairman, Radiation OncologyRon Rodriguez, M.D., Ph.D.Professor and Chairman, UrologyRobert S. Schenken, M.D. Professor and Chairman, Obstetrics & GynecologyRandal A. Otto, M.D., FACS Professor and Chairman, OtolaryngologyFrank Miller, M.D., FACSProfessor and Deputy Chairman, OtolaryngologyDirector, Head and Neck SurgeryGlenn A. Halff, M.D.Director, UT Transplant Center and Professor, Surgery David F. Jimenez, M.D.Chairman, NeurosurgeryRobert H. Quinn, M.D.Professor and Chairman, Department of Orthopaedics Anne-Marie Langevin, M.D.Professor, Pediatric Hematology/OncologyGail Tomlinson, M.D., Ph.D.Chief, Pediatric Hematology/OncologyHoward T. Wang, M.D. Chief, Division of Plastic & Reconstructive SurgeryAnand Karnad, M.D.Chief, Hematology/OncologyJohn Sarantopoulos, M.D.Interim Director, Institute for Drug DevelopmentSteve Weitman, M.D., PhDCo-Program Director, Institute for Drug DevelopmentSandra S. Osswald, M.D.Chief, Dermatology and Cutaneous Surgery

Ian M. Thompson Jr., M.D.Director

SENIOR LEADERSHIP LEADERSHIP


97Cancer center members

162Open clinical trials

1,525Accrual to clinical trials

3,341New patients

CTRC BY THE NUMBERS

55%Patient Revenue

46%Salaries &Benefits

28%Grants &Contracts 29%

Supplies &Equipment

15%Contributions 22%

OutsideServices

2%Other

3%Other

55%Patient Revenue

46%Salaries &Benefits

28%Grants &Contracts 29%

Supplies &Equipment

15%Contributions 22%

OutsideServices

2%Other

3%Other

CTRC fundingThe CTRC manages a budget of more than $53 million to support the entire range of activities of a National Cancer Institute-designated cancer center including patient care, research, education and operations. Just over half of the support comes from clinical revenues and nearly one-third from contracts. An increasingly important component of this support comes from contributions, which totaled more than $8 million in 2015.

CTRC use of funds by type

CTRC funding source


Happiness is having had cancer and

living to tell about it. Thanks, CTRC.

“ “PATIENT CARE


The pain in Sasha Perales’ lower back had become unbearable. But how could this 24-year-old have so

much back trouble at such a young age, she and her family wondered? A chiropractor had performed

adjustments of her spine without improvement.

In December 2014, Perales’ unyielding pain forced her to make a trip the emergency room at University

Hospital. There, MRI scans of her back revealed her worst nightmare – cancer destroying several bones in her body –

most of her spine, part of her hip and several ribs.

Soon, Perales was unable to walk and needed continuous infusion of pain medications into her veins around the clock. A biopsy of an enlarged lymph node revealed that this

cancer was a rare type – alveolar rhabdomyosarcoma. It was Stage 4. Rapid interdisciplinary discussions and care plans were put in place with the help of comprehensive care teams

including orthopedic oncology, medical oncology, pediatric oncology (children’s cancer doctors have great expertise in this cancer – more common in children), radiation oncology, palliative care and medicine. Together, they worked tirelessly on a complex treatment plan for Perales consisting of chemotherapy and radiation treatments.

Remarkably after consistent treatment, Perales was soon transformed from a bedridden patient into one who

won over the hearts of all. Her determination to live and her commitment to her treatment

motivated medical fellows and residents and brought joy to the nurses caring for her.

In January of 2015, Perales was discharged from University Hospital. A few months later she no longer needed to take pain medication. Now, a year later she continues to fight her cancer with the help of teams at the CTRC, University Hospital and most importantly, her friends and family at home who have rallied support and raised funds for her treatment and care.

Perales remains determined. She signed up to complete college credits, continues to arrive at all her medical appointments with a dazzling smile and cheers up even the most fatigued staff member in her midst. Her upbeat and determined personality continues to inspire a generation of oncologists in training.

Understanding that the cure for rare cancers requires teams of people working together, Perales has often served to inspire teams to achieve goals that seem out of reach while she pushes on with her family and friends to improve and beat the disease. She always finds time for a kind word for all and never gives up on her oncologist or her trust in him to care for her.

Rare cancers matter. Sarcomas are deadly. Entire teams are needed to help patients with sarcoma prevail and thrive. Sarcoma research teams at the CTRC collaborate with physician-scientists from all over the world to understand the nature of this type of cancer and bring new treatments to the bedside. But it is patients like Perales who truly inspire a whole range of professionals to fight harder and reach for cures.

Patient inspires cancer teams to win battle

Anand Karnad, M.D. (left), a professor of medicine and chief of the Division of Hematology-Oncology at the CTRC, examines his patient Sasha Perales.


Patient inspires cancer teams to win battle


In late 2014 Patti Swicegood, 61, found a lump in her breast. The news was devastating. The mass turned out to be an aggressive triple negative cancer. Swicegood immediately began conventional treatment and underwent surgery, but only to soon learn in May of that year that the cancer had metastasized to her lungs. Her doctors told her she probably didn’t have much time left.

“When the doctor tells you that you have four to six months to live, four is what you hear,” Swicegood said. “And then the weeks go by and you just feel like your life is ticking away.”

Her pain began to increase and she had developed an ominous cough every time she spoke.

“I just felt like there may be no hope,” Swicegood said. “We didn’t think I would make it for the holidays that year.”

That’s when the Pflugerville resident found her way to Virginia Kaklamani, M.D., D.Sc., leader of the breast oncology program at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio.

And Dr. Kaklamani told her she had options.

“The attitude of the two doctors could not have been more positive,” Swicegood said. “Dr. Kaklamani’s attitude is, ‘We’ve got stuff to do here. We’ll try this, and if that doesn’t work we’ll plug in something else.’”

The clinical trial that Dr. Kaklamani offered Swicegood is for an immunotherapy drug. The promise of immunotherapy is becoming a reality in more and more cancers, and at the CTRC it is offering hope to patients through clinical trials for triple negative breast cancer.

“When patients come in who have exhausted all available therapies, we will talk about what trials are available for them here,” Dr. Kaklamani said. “We want to get the best possible therapy for their particular cancer.”

Triple negative breast cancer is more difficult to treat, and does not respond to three types of hormonal therapies commonly effective in other breast cancers.

Unlike chemotherapy, immunotherapy does not kill cells. It strengthens the immune system so that the system can do its work.

“The immune system does fight cancer cells, but clearly it cannot always defeat them, and the cancer grows and spreads,” Dr. Kaklamani said.

“We have found that in these cases the cancer cells have sent a signal that fools the immune system into thinking that cancer isn’t foreign, and therefore the system doesn’t attack the cancer cells.”

Dr. Kaklamani said that by interfering with this signal, the drug tells the immune system what the cancer really is, and the immune system can then do its job to kill the cancer cells.

“Antibodies are a weapon of the immune system that circulate through the body’s cells until they find a protein called an antigen,” Dr. Kaklamani said. “They can attach to that antigen and call in other parts of the immune system to destroy the cells containing the antigens. In immunotherapy,

from hopeless to healing

Dr. Virginia Kaklamani is associate director of clinical research and leader of the breast oncology program at the CTRC.


months suddenly disappeared and the feeling of hope overwhelmed me.”

Patti and her husband, Allen Swicegood, immediately began planning for the holidays, when the amiable, white-bearded Allen most enjoys dressing up and playing the role of Santa Claus at holiday gatherings with family and friends. He was elated that he knew he would surely have his “Mrs. Claus” beside him that year.

“Dr. Kaklamani and her whole staff have really changed our lives,” Allen Swicegood said. “I’m very optimistic that my wife is going to be a hero here.”

To see Patti Swicegood’s inspiring story on video, visit: vimeo.com/uthscsa/videos

researchers design antibodies that target the specific antigens found on cancer cells. They can create multiple copies of these antibodies, known as monoclonal antibodies,” she said.

Dr. Kaklamani said patients can respond very differently to medications, and that’s why carefully monitored clinical trials are so important in drug development.

“In Patti Swicegood’s case, she had a mild allergic reaction, but her cough began to subside and she quickly started to feel better,” Dr. Kaklamani said. In early September, Swicegood underwent tests. Four months after receiving the news that she didn’t have much time to live, new tests showed the cancer was significantly smaller.

“There are not adequate words to describe the feeling of relief that floods over you,” Swicegood said. “This huge dark cloud that hung over us for

THE NAVIGATOR IS:

• A dedicated registered nurse who answers cancer or other health-related questions

• Available by telephone or face-to-face visits with partners and their families

• Available toll-free Monday-Friday, 8 a.m. to 5 p.m. with bilingual assistance

THE NAVIGATOR CAN:

• Schedule and coordinate all treatment options and appointments

• Schedule and coordinate a second opinion

• Provide important information and resources specific to your condition

• Coordinate community resources such as travel and life issue assistance

• Remind and follow up on appointments and treatments as needed

• Coordinate directly with your insurance (BCBS), Pharmacy (Med Impact & Diplomat), mental health (Compsych), and leave (Cigna) contacts

• Get answers to benefit and billing questions

TOLL-FREE CANCER CARE HOTLINE 1-855-469-4321

Thanks to a partnership between the CTRC and H-E-B, Patti Swicegood found treatment that kept her alive. The H-E-B Partner Care Navigator program is designed to help H-E-B employees and their families who are diagnosed with cancer.

The service is free and confidential for H-E-B partners and is staffed by a registered nurse who is available to help patients and their families no matter where they live or where they receive treatment.

“I cannot begin to express how thankful I am to our H-E-B patient navigator Kathryn Eggerss for directing us to Dr. Virginia Kaklamani and her staff at the CTRC and for what they have done for me and my whole family,” said Patti Swicegood, CTRC patient and cancer survivor. “Their encouragement and compassion through this has been awesome! They are truly miracle workers and I will be forever grateful.”

CTRC/H-E-B PARTNERSHIP GUIDES PATIENT TO SURVIVAL

Allen and Patti Swicegood


https://vimeo.com/uthscsa/videos


CTRC conducts Phase 2 testing of new agent

lioblastoma is an aggressive brain cancer that kills two-thirds of patients within five years. A patient’s outlook with recurrence of the disease is considered to be weeks or months.

But researchers at the Cancer Therapy & Research Center at the UT Health Science Center San Antonio report that a gene therapy being studied there has essentially doubled the overall survival of patients with recurrent glioblastoma compared to the current standard of care.

CTRC medical oncologist Andrew J. Brenner, M.D., Ph.D., associate professor in medicine, neurology and neurosurgery at the UT Health Science Center School of Medicine, presented final results of a Phase 2 clinical research study that evaluated the gene therapy, called VB-111, in continuous and intermittent doses and in comparison to the treatment standard, the chemotherapy Avastin™. Patients receiving VB-111 survived 15 months on average, compared to eight months on average for patients receiving Avastin alone. The CTRC and three other centers enrolled 62 patients with recurrent glioblastoma for the studies.

“These are the patients with the most serious cases, whose glioblastoma has recurred after surgery and who, as a result, have a very short life expectancy,” Dr. Brenner said.

Dr. Brenner, principal investigator for the studies, presented the results at the European Cancer Congress meeting in Vienna, Austria. “In addition to the benefit in overall survival, VB-111 was safe and well-tolerated in the patients, and proved to be effective both as a single therapy for recurrent glioblastoma and in combination with Avastin,” he said.

The improvement in overall survival is clinically significant. “These numbers compare favorably to any current benchmark in recurrent glioblastoma

and may change the treatment paradigm for these patients,” Dr. Brenner said.

“I am very proud of the work of Dr. Brenner and his team who are setting the stage for breakthrough advances in the treatment of brain cancer here at the CTRC,” said Ian Thompson Jr., M.D., CTRC director. “We are also especially thankful that Dr. Brenner is helping lead the large team of scientists and physicians who are developing next-generation cancer treatments at our cancer center.”

Phase 2 studies, conducted after first-in-human studies, add detail about the effectiveness and safety of experimental treatments for disease. VBL Therapeutics of Tel Aviv, Israel, maker of VB-111, recently launched a Phase 3 clinical research study of the drug to provide more detail.

The CTRC is currently the only site open for the Phase 3 trial, with the first patients enrolled here in San Antonio. Approximately 50 more sites in North America, Israel and Canada were added in November 2015.

James Burrows (pictured left with Dr. Andrew Brenner) was successfully treated with VB-111 therapy at the CTRC.

A press conference was held Oct. 1, 2015 to highlight the findings of Dr. Brenner’s clinical trial. Television and radio stations captured the story of James Burrows and his promising outcomes resulting from his participation.


CTRC means hope and faith. Hope for a cure and faith that

the wonderful staff at the CTRC is doing everything they can

to help my dad survive!

“ “RESEARCH


Atrip to her lab at the CTRC for Donna Ankerst, Ph.D., isn’t your ordinary daily office commute. That’s because in

addition to being a full-time faculty member at the CTRC and in the Department of Epidemiology and Biostatistics at the UT Health Science Center San Antonio, Dr. Ankerst is also a professor of mathematics at the Technical University of Munich, Germany (the Technische Universität München).

“The CTRC is indeed fortunate to have such an accomplished leader in the field as Dr. Ankerst who travels to San Antonio regularly to accelerate discovery in this important scientific area,” said Ian M. Thompson Jr., M.D., director of the CTRC.

Dr. Ankerst’s association with the CTRC began with her collaboration with Dr. Thompson while she pioneered the development of a sophisticated tool to predict a man’s risk of prostate cancer.

Based on more than 5,500 men who were followed for seven years, version 1.0 of the tool incorporated a range of risk factors including, PSA, family history, prostate exam findings, age, race/ethnicity and family history of prostate cancer. It also provided an estimate of a man’s risk of cancer.

SP TLIGHT on Donna Ankerst, Ph.D.

(Left) Dr. Ankerst developed a sophisticated tool, which is used worldwide, to predict a man’s risk for prostate cancer. Version 2.0 (pictured left) uses “emoji’s” to help patients understand their risk and make individualized, personalized decisions regarding their medical care. Dr. Thompson said this tool is the most sophisticated cancer risk tool available to physicians today.

(Above) Dr. Ankerst (far left), is pictured with Ph.D. students and post-doctoral fellows from the Technical University in Munich, Germany. They are (left to right) Norbert Krautenbacher (standing behind Dr. Ankerst), Michael Laimighofer, Christoph Kurz, Christiane Fuchs, Hagen Scherb, Ivan Kondofersky and Julia Söllner.

Version 2.0 employs “emoji’s” to help patients understand their risk and make individualized and personalized decisions regarding their medical care. Dr. Thompson said the tool, which is used around the globe, is the most sophisticated cancer risk tool available to physicians.

Dr. Ankerst is expanding her work into the breast cancer field. She is working with Virginia Kaklamani, M.D., D.Sc., who leads the CTRC’s breast oncology program. Dr. Ankerst is also co-directing a pioneering program to develop a risk calculator for prostate cancer that works within

the electronic health system to continuously update a patient’s risk, which can vary considerably from institution to institution.

Dr. Ankerst earned her B.S. from The University of Texas at Austin, her master’s degree and Ph.D. in statistics at Carnegie Mellon University and completed a National Science Foundation Mathematics Postdoctoral Fellowship at Harvard University.

In her various roles at London’s University College, the Massachusetts General Hospital and the Fred Hutchinson Cancer Research Center in Seattle, Dr. Ankerst has worked with or led some of the most prominent statistical research groups in the world.


DISCOVERY OF THE YEAR AWARD

Ratna Vadlamudi, Ph.D., professor in the Department of Obstetrics and Gynecology, and Yanfen Hu, Ph.D., associate professor in the Department of Molecular Medicine, are co-recipients of the Cancer Therapy & Research Center’s (CTRC) 2015 Discovery of the Year Award.

Dr. Vadlamudi studies estrogen receptor (ER) signaling and originally discovered PELP1 as a proto-oncogene that is dysregulated in cancer. He was selected as one of the winners of CTRC Discovery of the Year based on his recent findings published in the journal Cancer Research, in which he demonstrated that PELP1 dysregulation promotes ER+ breast tumors in vivo and provides new clues into the molecular basis of ER+ breast tumor development and progression.

Dr. Hu was also honored with the CTRC Discovery of the Year Award for her work on the BRCA1 gene, which was published in the journal Cell Cycle earlier this year. Her research offered unprecedented mechanistic insights into BRCA1 function in tumor suppression and demonstrated the role of BRCA1 in DNA repair.

CTRC honors investigators for outstanding contributions to cancer research

CLINICAL INVESTIGATOR OF THE YEAR AWARD Anne-Marie Langevin, M.D., professor of pediatrics and a pediatric oncologist, has been a crucial part of the efforts of the CTRC to ensure that San Antonio children have access to clinical trials. That’s why this year, she was selected as the CTRC’s Clinical Investigator of the Year.

Dr. Langevin has taken a lead role in pediatric cancer clinical trials. Over the past year she has successfully completed and obtained a large National Institutes of Health (NIH) infrastructure award to support clinical trial enrollment of minority children onto cancer therapeutic and cancer control studies at San Antonio institutions including University Hospital and Methodist Children’s Hospital as well as Dell Children’s Medical Center in Austin.

Moreover, she accomplished this during the time of a challenging hospital transition. She is also the lead clinical investigator on the Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC) early phase drug trial consortium for pediatric patients. The mission of POETIC is to promote the early clinical development of promising therapies for the treatment of children, adolescents and young adults with cancer and related disorders. Dr. Langevin is truly making a difference in the lives of children throughout South and Central Texas.

Dr. Hu Dr. Vadlamudi

Dr. Langevin (left) with CTRC Deputy Director, Dr. Tim Huang


Cancer is much more likely in the elderly than the young, and their bodies often are less prepared to fight the disease and the often-toxic side effects of treatment.

But a new study at the UT Health Science Center San Antonio shows that some types of immunotherapy previously thought to work only in younger patients can be used to help the elderly, with less toxic effects than many common therapies, if combined in ways that account for age-related changes in the immune system.

“We’ve shown that immunotherapy for cancer not only works in aged mice, but actually can work better in aged hosts than in young counterparts by capitalizing on the immune changes that happen with age,” said Tyler Curiel, M.D., M.P.H., a professor in the School of Medicine at the Health Science Center and principal investigator of the study, published in the journal Cancer Research.

“As you age, most parts of your body begin to wear out. They keep doing what they’re made to do,” Dr. Curiel said. “But over time, they don’t do it as well. The general perception is that the immune system also simply declines with age. That’s really too simplistic. That’s really not the full picture of what’s happening,” he said.

The body’s immune system does weaken with age, but it also changes, and that changes the rules for fighting disease within the body.

“We’ve shown that an aged immune system can combat cancer just as well as a young one if you remove the impediments to successful immunity, which are different than those in younger hosts,” Dr. Curiel said. “We’ve shown that if you test all your immune therapy just in young mice and young people, you’ll never learn how it works in older patients – the ones most at risk for cancer. You might conclude that drugs don’t work in aged hosts, when they do. But they have to be combined with some help.”

After discovering this in melanoma, the researchers then looked at whether the same held true in colon cancer, a major cancer killer in the elderly.

“The details were different in colon cancer. The bad immune cells that increased in the aged mice and how they were knocked down by the drugs were different than in melanoma,” Dr. Curiel said. “But the result was the same. We identified a drug combination that was highly effective in the aged mice.”

That means that not only must this strategy be developed with regard to the age of the patient, he said, it also must be specific to the cancer.

“It’s a bit complicated, but it’s possible to put into practice, and because these approaches could be so much more specific and so much better tolerated than conventional chemotherapy, it is well worth pursuing. We are grateful to the Voelcker Foundation and the Holly Beach Public Library Association for funding this work,” Dr. Curiel said.

Immunotherapy for elderly cancer patients finds new promise in drug combination


Only a third of patients with late-stage oral cancers survive five years after their diagnosis, and the pain they endure defies description. That’s why the research of the Cancer Therapy & Research Center’s (CTRC) Cara Gonzales, D.D.S., Ph.D., also an assistant professor of comprehensive dentistry at the UT Health Science Center, is so vital and exciting.

Born and raised in San Antonio, Dr. Gonzales has had an interest in biology since she was a student at Incarnate Word High School. After receiving her bachelor’s degree from St. Mary’s University, Dr. Gonzales found Ellen Kraig, Ph.D., professor of cellular and structural biology in the School of Medicine, who gave her a job and the research experience she needed to be admitted as a doctoral student in 1995.

Dr. Gonzales was studying the genetics of inherited tooth disorders and received her D.D.S. and Ph.D. degrees in 2003.

Over the years, numerous investigators aided different phases of her development. CTRC faculty member Ken Hargreaves, D.D.S., Ph.D., professor and chairman of endodontics and professor of pharmacology, physiology and surgery, has been her mentor since 2006 when she first shifted her research focus toward oral cancer and cancer pain. His experience and advice were critical to Dr. Gonzales becoming an independent investigator.

In this way, Dr. Gonzales became a clinician-scientist. “It wasn’t planned, and yet it worked out exactly the way it should have,” she said. “Getting the dental degree enabled me to do so much more with my cancer research than I could ever have done otherwise.”

Another mentor, Susan Mooberry, Ph.D., professor of pharmacology, is co-leader of the Experimental and Developmental Therapeutics Program at the CTRC. She has guided Dr. Gonzales as her research expanded into drug discovery and development.

Dr. Gonzales and her team recently reported that mouse models of human oral cancer, when treated with an agent called capsazepine, show dramatic tumor shrinkage. Capsazepine kills the cancers selectively; it leaves normal tissues unharmed and also acts on neurons to block pain. “This is a very desirable combination in a potential medication,” she said.

So far, only local administration of capsazepine, directly into the primary tumors, has been tested in mice. Because many patients with oral cancer have disease that has spread, Dr. Gonzales and her team are developing novel drugs similar to capsazepine that can be delivered systemically, to reach metastatic disease that is not easily accessible.

“The overall survival rates for oral cancer patients with advanced disease have not changed in nearly 40 years,” Dr. Gonzales said. “Ultimately, our goal is to develop new therapies to improve survivorship of this insidious disease.”

On a personal level, Dr. Gonzales has witnessed the suffering of patients and family members with cancer. “While I was in graduate school, my grandmother died of lung cancer and my aunt died of pancreatic cancer,” she said. “That saying, ‘everyone is touched by cancer,’ is true. Once you witness it, you feel compelled to do something about it.”

DENTIST DELVES INTO CANCER RESEARCH

Dr. Cara Gonzales


Since joining the CTRC in 2010, Robert Svatek, M.D., and his team have dramatically impacted the field of bladder

cancer research and care on a national scale. Through CTRC’s affiliation with the Southwest Oncology Group (SWOG), Dr. Svatek has not only provided national leadership for enrolling patients in cutting-edge clinical trials but has also led the roll-out of one of the most innovative studies in the United States. Examples of his work include helping lead accrual for S0337, a study evaluating a new drug for localized bladder cancer – gemcitabine; the CTRC teams’ involvement ensured the study’s national success by enrolling more than 50 patients in two years. Dr. Svatek also co-leads S1011, a study evaluating the role of lymph node removal during surgery for bladder cancer. As of Nov. 22, 2015, the UT Health Science Center San Antonio has enrolled 39 patients.

Dr. Svatek also has an active research program, studying both the biology of bladder

cancer as well as how to improve the lives of bladder cancer patients. His work has been funded by an institutional KL2 grant award

and a prestigious Young Investigator

Award from the Max and Minnie Tomerlin Voelcker Fund. He is also the recipient of a National Cancer Institute (NCI) of the National Institutes of Health (NIH) K23 Mentored-career Development Award.

If Dr. Svatek sounds busy, it is because he thrives on meeting new challenges. He says he has always been drawn to caring for patients with challenging conditions.

“I remember deciding early on during my urology training that I would either focus on patients who sustained a spinal cord injury or patients suffering from bladder cancer because, to me, these two populations experienced problems that were incredibly demanding and challenging,” Dr. Svatek said. “Ultimately, I chose the field of bladder cancer as I was particularly interested in Bacillus Calmette-Guerin (BCG) immune therapy. “I found it remarkable that bacteria instilled into the bladder could completely eradicate early-stage bladder cancer. “This fascinated me when I first saw it many years ago, and it still does today,” he said.

Dr. Svatek came to San Antonio after meeting Ian M. Thompson Jr., M.D., CTRC director, who was, at the time, chair of the Department of Urology. Dr. Svatek said it all began with a paper published

COLLABORATION AND RESEARCH ADVANCE BLADDER CANCER TREATMENT


by Dr. Thompson in 2003, while he was in his first rotation as a urology resident. The New England Journal of Medicine published results of a randomized trial demonstrating that the drug finasteride could prevent prostate cancer. As Dr. Svatek remembers, “The work was a worldwide sensation and remains one of the biggest achievements of our field,” he said. “I spent weeks examining the article and subsequently spent 18 months modeling the economic impact of finasteride for cancer prevention. That was my first exposure to research and I was captivated.”

Dr. Svatek soon met Dr. Thompson who quickly became a role model and mentor to him almost a decade before Dr. Svatek ever made it to San Antonio.

Dr. Thompson recognized Dr. Svatek’s talent immediately, stating, “Robert Svatek has the talent, drive and focus to become one of the top cancer luminaries of this century in the U.S. He has declared war on bladder cancer and is using basic science, early clinical trials and the NCI’s clinical trial network to dramatically increase cure rates from this terrible disease.” Dr. Svatek was honored in 2015 with the Health Science Center’s Presidential Distinguished Junior Research Scholar Award.

Dr. Svatek’s most recent accomplishment has been to take the science of the CTRC into a national clinical trial. In September 2015, the NCI approved S1602, a large randomized clinical trial that Dr. Svatek is leading. Based on work at the CTRC on the body’s immune system, the trial will answer two questions: whether different strains of a bacteria (Bacillus Calmette-Guerin or BCG) used to target aggressive early stage bladder cancer affect cancer cures; and whether “BCG priming” with a skin vaccination will further improve a bladder cancer cure.

Robert Svatek, M.D.Assistant Professor, UrologyUT Health Science Center San Antonio

To read more about Dr. Svatek, visit

uthscsa.edu/patient-care/ctrc/ providers/dr-robert-svatek

http://www.uthscsa.edu/patient-care/ctrc/providers/1922216431/Dr.-Robert-Svatek


Two pediatric researchers from San Antonio are launching a new study to learn more about predicting heart problems in adults

who are survivors of childhood cancers.

“A third of long-term survivors have a life-threatening medical problem related to the treatment that saved them,” said Greg Aune, M.D., Ph.D., an assistant professor in the Department of Pediatrics at The University of Texas Health Science Center at San Antonio and co-principal investigator on the study. Dr. Aune, a survivor of childhood cancer, ought to know.

“You save someone’s life at 15 but they’re dead by the time they’re 50? You have a problem there,” Dr. Aune said.

This survivorship issue is a relatively new one, as more and more children with cancer are successfully treated and are living to adulthood. The problem is that the treatments that save them often cause problems down the road.

Dr. Aune is a perfect example of this. Diagnosed as a teen with Hodgkin’s disease, he endured the treatments, recovered and went on to become a physician scientist. After coming to the Health Science Center to begin a fellowship in pediatric hematology-oncology, the father of four was diagnosed with severe aortic stenosis and coronary artery disease. Now heart problems caused by early cancer treatments are his primary focus in research and clinical care.

In his laboratory at the Greehey Children’s Cancer Research Institute (GCCRI) at the UT Health

DOUBLE-TIMEDOUBLE-TIMEResearchers work to save young lives – twice

twiceScience Center San Antonio, Dr. Aune is working on a series of studies that examine the cardiac “late effects” that occur in pediatric mice exposed to chemotherapy. Then, in this study, Dr. Aune and principal investigator Helen Parsons, Ph.D., M.P.H., extend laboratory models directly to patients by enrolling survivors of childhood cancers to evaluate the diagnostic capabilities of cardiac MRI.

“We know that cancer survivors treated with certain drugs have a higher risk of heart problems,” said Dr. Parsons, an assistant professor in the Department of Epidemiology and Biostatistics. “But we don’t yet understand the types of people who are more at risk, and we don’t know the best technology to detect these problems early.”

Dr. Parsons indicates that other studies suggest cardiac MRI is a better tool than echocardiography, which is the current standard of care.” “However, they had very low Hispanic participation. Because South Texas has a unique population, she said it gives the researchers a unique opportunity to see how to best care for this growing population of cancer survivors.

Patients will complete a health survey and get a survivorship exam that looks for symptoms of possible late effects of their cancer treatment. Then they will receive an echocardiogram – a technique that uses sound waves to evaluate the pumping capacity of the heart – followed by a cardiac MRI for comparison.

(Above) Dr. Greg Aune

(Left) Dr. Helen Parsons

DR. AUNE ADDRESSES WORLD HEALTH ORGANIZATION

In September 2014, Dr. Greg Aune was appointed to the National Cancer Institute (NCI) Council of

Research Advocates. He said the two-year appointment is giving him the opportunity to help align the interests of myriad childhood cancer advocacy groups with those of the NCI.

“In doing so, I hope to encourage a meaningful dialogue regarding the future funding priorities for pediatric cancer,” Dr. Aune said. “I’d like to direct the obvious passion of these groups toward efforts that resonate

with the NCI and move the field of pediatric cancer research forward.”

The NCI Council of Research Advocates is the only federal advisory committee comprised of advocate leaders at the NCI. The council focuses on research-related issues and on enhancing community input, outreach and strong collaborations to improve research outcomes.

“This is a group consisting mostly of community advocates, but they really like the fact that Greg is both a cancer survivor and a cancer researcher,” said Gail Tomlinson, M.D., Ph.D., professor and the Greehey Distinguished Chair in the Genetics of Cancer at the GCCRI. “And they are undoubtedly as impressed as we are by his passion for what he does.” she said.

Dr. Aune also recently had the opportunity to represent childhood cancer patients, families and advocates from all over the world when he addressed the 68th World

Health Organization (WHO) Assembly in Geneva in May 2015. In his speech, he asked the Assembly to designate childhood cancer as a top global health priority. The Assembly is attended by delegations from all 194 WHO member states as well as by representatives from international organizations and civil society organizations. At the closing of his inspiring address, Dr. Aune said:

“I would like to end my time tonight by discussing for a moment the concept of hope. A British author wrote the following about the power of hope: There is no medicine like hope, no incentive so great, and no tonic so powerful as expectation of something tomorrow.

My personal journey is a testament to the hope that we can offer all children and families impacted by childhood cancer. Never before have children with cancer faced a tomorrow with a medicine as powerful as the hope that we can instill by coming together as a global community to address this problem. We can do better. We must do better. It is in fact our duty.”

To read more about Dr. Aune and his research team, visit

uthscsa.edu/stories/cardiac-research-pediatric

http://gsbs.uthscsa.edu/faculty/ greg-aune-m.d.-ph.d

uthscsa.edu/patient-care/ctrc/providers/ dr-gregory-aune


http://www.uthscsa.edu/stories/cardiac-research-pediatric

http://gsbs.uthscsa.edu/faculty/greg-aune-m.d.-ph.d

http://www.uthscsa.edu/patient-care/ctrc/providers/1609920073/Dr.-Gregory-Aune


CTRC means

everything to me!

“ “CLINICAL TRIALS


“

ife is a journey. It is about searching for our purpose in life and achieving our goals. For Woondong Jeong, M.D., life is all about hope. Dr. Jeong decided to become an oncologist because he wanted

to give patients suffering from incurable cancers the gift of hope. He began his career as a community-based oncologist working in a private practice, but soon found that clinical research was his calling.

“My heart ached every time I had to tell my patients with terminal illness that there are no other treatments available for them,” Dr. Jeong said. “I did not want to give up on them, and as their doctor, I desperately wanted to be able to provide more treatment options for them.”

His passion for cancer drug development led Dr. Jeong on a nearly 7,000-mile journey from his home in Seoul, South Korea, to the Cancer Therapy & Research Center (CTRC) in San Antonio, Texas.

Dr. Jeong said his journey has been remarkable, and one that he takes very seriously. That’s because he treats each patient as a good friend.

Dr. Jeong is inspired by his patients. He shared the story of one of his patient’s recent battle against metastatic bladder cancer. His patient had been diagnosed with lung metastases, a grim diagnosis, and was placed under Dr. Jeong’s care. Using new technology, Dr. Jeong and his CTRC colleagues were able to identify a fibroblast growth receptor mutation in the patient’s tumor. This opened the door for the patient to enlist in a targeted therapy

leads researcher on nearly 7,000-mile journey to CTRC

trial, which led to nearly complete remission of the lung metastases giving the patient another six months to live.

At the six-month mark, the patient was no longer responding to the targeted therapy and began to experience shortness of breath and coughing. Dr. Jeong found that the tumor was growing again. The patient was then placed on a second trial but unfortunately his symptoms worsened and Dr. Jeong removed him from the trial.

At this point, his patient became gravely ill. However, he was strong and not ready to give up. Dr. Jeong and his patient waited for a slot on an immunotherapy trial and the patient remained relatively stable on chemotherapy.

Currently, Dr. Jeong said this particular patient continues the good fight under his watchful eye, and is now more like his old buddy. His patient is now enrolled in an immunotherapy drug trial.

Recently, Dr. Jeong and his patient sat down and like many old friends, they had a long talk about end-of-life issues and bucket lists.

“He said he has no regrets about his life, and that even if this is the last treatment that works and he is never cured, he is completely happy because he knows he did his best to fight it,” Dr. Jeong said about his patient.

He and Dr. Jeong never gave up hope. “Along our journey, we will be confronted with many situations and challenges testing our courage, strength and faith,” Dr. Jeong said. “We may stumble upon obstacles on the paths we take, but we must overcome these obstacles. I was blessed to meet and treat my patient. I learned so much from him and about what we should value in life. He gives me strength to continue on my journey finding cures for untreatable cancers.”

I was frustrated that I couldn’t do more for my patients and had to refer them to academic centers far away because I didn’t have access to early clinical trials during my private practice,” Dr. Jeong recalls. “That’s why I decided to change my career to drug development — to expand my treatment options past traditional chemotherapy.”

Dr. Woondong Jeong


A clinical trial can mean the difference between life and death for a cancer patient.

But before a new treatment or drug can be made available to patients with cancer and approved by the U.S. Food and Drug Administration (FDA), a step-wise “clinical trial” approach is undertaken. The concept of clinical trials in patients with cancer is relatively new and evolving. The concept of the modern-day clinical trial began in the post-World War II era. The first randomized clinical trial in cancer conducted at the National Cancer Institute (NCI) was planned in 1954 and commenced in 1955. This first study focused on a new treatment for patients with acute leukemia.

Since those early days, clinical trials have evolved, with the help of institutions like the Cancer Therapy & Research Center (CTRC), into a multi-step (or phases) process. The ultimate goal of these different phases is to determine, using as efficient a process as possible, whether a new treatment is clearly effective and safe for patients with cancer.

There are generally four to five phases of clinical trials that are undertaken. The most common approach involves the first-in-human Phase 1 study, followed by sometimes multiple Phase 2 and 3 studies. There are Phase 0 and Phase 4 studies, which are typically not critical for the development of a new cancer therapy, but occasionally are undertaken, or even at times required by the FDA.

KEY POINT:

Prior to approval by the FDA, it is common to consider a new treatment using terms such as “agent” or “compound,” but only after approval by the FDA does the new treatment earn the right to be referred to as a “drug.”

• PHASE 1: A PHASE 1 STUDY IS USUALLY THE FIRST TIME A HUMAN BEING HAS BEEN TREATED WITH A NEW ANTICANCER COMPOUND. These are typically smaller studies conducted at a limited number of highly specialized centers such as the Institute for Drug Development (IDD) at the CTRC and may involve only 30-45 patients with a variety of cancer types. The key focus of these studies is to determine the safe dose and potential side effects of a new agent. In addition, while not the main focus of the study, looking for anti-tumor activity is also a component of these early studies. Phase 1 studies typically take about 18 months to complete.

• PHASE 2: ONCE A SAFE DOSE HAS BEEN IDENTIFIED, A PHASE 2 STUDY MAY BE CONDUCTED IN APPROXIMATELY 45 TO 60 PATIENTS. While it is still a goal of these studies to further understand the safety profile of a new agent, the major focus of these studies is to understand whether a new treatment has enough anti-tumor activity to warrant moving forward. While Phase 1 studies are conducted in a variety of cancer subtypes, Phase 2 studies are generally undertaken in very specific subtypes of cancer such as breast or colon cancer. Phase 2 studies typically take about one to two years to complete.

• PHASE 3: IF A NEW TREATMENT HAS BEEN SHOWN TO HAVE PROMISING ANTICANCER ACTIVITY IN A PHASE 2 SETTING, THEN TYPICALLY A PHASE 3 STUDY IS UNDERTAKEN. This study usually forms the basis for “approval” by the FDA. Phase 3 trials are large studies (200-850 or more patients) and almost always involve

Clinical trials are research studies that explore whether a medical strategy, treatment or device is safe and effective for humans. These studies also may show which medical approaches work best for certain illnesses or groups of people. The CTRC has more than 160 open clinical trials in all types of cancers ranging from colon, breast, brain, kidney, eye, leukemia and others. More than 4,000 patients have participated in early-phase trials at the CTRC.

WHAT IS A CLINICAL TRIAL?


randomization against the current standard-of-care for patients with a very specific indication. If a new treatment appears to be better (i.e., improves survival) than the currently

available standard-of-care treatment, then the FDA will typically grant marketing approval; making the new treatment available to everyone with a specific type of cancer. These studies can take years (three to five years) to conduct and to analyze.

KEY POINT:

The process of taking a new agent from the laboratory through the clinical trial process is very difficult and time consuming. Most new agents that enter a Phase 1 study never complete all phases of the clinical trial process and do not reach the goal of becoming a drug. This whole process can take sometimes 10-plus years to complete. However, there are new programs available such as “breakthrough therapy” designation that can dramatically shorten the timeline from discovery to approval.

The cancer investigators at the IDD and CTRC are constantly developing new therapies that emerge from their own laboratories or from a variety of outside programs. They are constantly asked to help design and conduct Phase 1-3 clinical studies based on their years of experience and leadership in helping patients with refractory cancer. For assistance or questions regarding cancer clinical trials, contact the CTRC at 210-450-1000.

KEY POINT:

The investigators at the IDD and CTRC use the most modern molecular techniques to identify the most appropriate new

therapy that targets your specific cancer. The cost of participating in a clinical trial is

typically covered by your insurance company or the sponsor of the study. It is important to discuss all questions with your primary oncologist at the CTRC.

To find a clinical trial at the CTRC, visit http://www.uthscsa.edu/patient-care/ctrc/clinical-trials

http://www.uthscsa.edu/patient-care/ctrc/clinical-trials


The best cancer center in the world

with the best physicians and staff; so caring,

patient, efficient and proficient.

“ “SERVICE ANDOUTREACH


“ Women who live in the Texas Lower Rio Grande Valley experience a higher risk of death from cervical cancer as compared to women who live in other parts of the state and nation.

Although vaccines are available to prevent cervical cancer, infrequent visits to health care providers, missed opportunities for vaccinations and the lack of health insurance have all been identified as barriers to receiving timely vaccinations.

Researchers at the CTRC have implemented new outreach and education strategies that engage the help of promotoras (lay community members trained to deliver health messages to parents/caregivers and adolescents), to overcome these health barriers. The promotoras use netbooks and collaborate with local community organizations and clinics to reach susceptible women in the community.

The initiative is an expansion of Entre Madre e Hija (EMH), a Cancer Prevention and Research Institute of Texas (CPRIT)-funded cervical cancer prevention and outreach program delivered by promotoras and student-peer educators to Hispanic women and their daughters who live in Hidalgo and Cameron counties in the Lower Rio Grande Valley. The promotoras provide health education, referrals and navigation support for human papilloma virus (HPV) vaccination to enrolled women whose daughter(s) have never been vaccinated or have not completed the vaccination series.

Implemented at three local community resource centers (two in Hidalgo and one in Cameron counties), the promotoras deliver group health education sessions to women. They also provide referrals and navigation for women who request assistance with vaccination appointments for their daughters.

A new partner, Nuestra Clínica del Valle, will also provide vaccinations to program participants; lists of vaccine eligible clinic patients to promotoras for recruitment purposes; and reports of vaccine status for program participants.

Researchers plan to expand the program’s reach to include 11- to 17-year-old Hispanic boys and their male caregivers, as well as expansion of its service area to include additional cities, community resource centers and clinic locations within Hidalgo County.

Researchers give South Texans resources to fight cervical cancer

The overall goal of the project is to increase HPV immunization rates (initiation and completion) using public education and clinic in-reach strategies among Hispanic adolescent males and females in clinics within Hidalgo County.

As a result, researchers estimate that from August 2014 to August 2016, they could reach approximately 3,000 Hispanic adult residents of Hidalgo County; educate 1,500 adult residents of Hidalgo County using the program’s evidence-based education sessions; could meet or exceed Texas’ vaccine initiation by 33 percent; complete a 10 percent rate for males; and meet the vaccine initiation by 88 percent, as well as completion rates of 46 percent for girls introduced to the initial program.

By increasing vaccine initiation and completion, the program could potentially reduce cervical cancer incidence and mortality among Hispanic women and men in the Texas Lower Rio Grande Valley region.


t only 18 years old, Lupita Martinez was in the hospital being treated for complications of lupus when the inspiration first surfaced.

While observing a social worker, the idea struck her that this vocation might be her calling.

However, when she entered college, Martinez opted to major in business. After graduation, she entered the business world. Gradually, her original love of social work lured her to change course.

“In my heart, I wanted to be a social worker,” Martinez recalls. “I found it very fulfilling helping people.”

Not one to shy away from a challenge, Martinez decided to pursue a Master of Business Administration degree at the University of Texas at San Antonio, while working simultaneously on a master’s degree in social work at Our Lady of the Lake University in San Antonio.

“I graduated on the same day from both schools,” she laughs as she recalls her dual educational accomplishment.

With her degrees in hand, Martinez followed her heart and became employed as a social worker at a nursing home and also worked with patients at a hospice care unit.

Those experiences eventually led her to the Cancer Therapy & Research Center (CTRC) where she serves as the social worker in the Patient and Family Services Division.

In her job, she works with cancer patients to solve

and cope with the myriad problems encountered as a result of the disease. Counseling also is an important part of her role at the CTRC.

“People dealing with cancer need someone to listen to their personal and family issues,” Martinez said. “Sometimes they find it easier to talk to a social worker who understands their needs.” Oftentimes doctors and nurses send patients to her office where Martinez assists with everything from paperwork for disability claims to securing needed resources such as walkers and canes.

She evaluates the needs of every patient, helping each one individually to cope with the life-disrupting nature of cancer.

“Usually, finances are an issue,” she said. “I can assist with food stamp applications, or arrange for Meals on Wheels. My goal is to help ease the burden of cancer.”

In her quest to help patients, Martinez has written letters to consulates of foreign countries to allow families living abroad to visit patients receiving treatment at the CTRC. In another case, Martinez worked with the state prison system to relocate an inmate closer to San Antonio so the patient could visit the family while receiving treatment.

“Whatever it takes,” Martinez said with a smile. “My job allows me to get awfully close to our patients. I feel like I am on the journey with them.”

That attitude is what makes Lupita Martinez a patient’s best ally in the fight against cancer.


umor boards represent an approach to treatment planning in which a number of doctors who are experts in diverse medical

specialties review and discuss the medical condition and therapeutic options for a patient. In cancer treatment, a tumor board may include a medical oncologist, surgical oncologist, radiation oncologist and radiologist, among other specialists, depending on the patient’s condition. The Cancer Therapy & Research Center (CTRC) at the UT Health Science Center San Antonio’s tumor boards are also open to referring physicians in the community who may be interested in participating in treatment planning for their patients.

The CTRC is unique in South Texas for the wide array of sub-specialty care its doctors can provide. This broad range of cancer expertise has not traditionally been available in outlying communities in the region.

To meet this growing need, the CTRC has developed virtual tumor boards to assist with cancer management at sites throughout South Texas. The goal is to provide patients with access to a multidisciplinary team, virtually, so that the patient does not have to travel far distances to the CTRC. Anand Karnad, M.D., chief of the Division of Hematology/Oncology at the CTRC, is leading this effort.

The first virtual tumor board, which meets on a monthly basis, was established at Doctors Hospital at Renaissance (DHR) in Edinburg, Texas, with support from a grant from the Delivery System Reform Initiative. After a series of planning visits to Edinburg, the CTRC established an internet-based video-audio link to connect face-to-face with physicians at DHR to develop treatment plans for patients with multiple types of cancer. A broad range of cases have been presented and, in many cases, a treatment plan has been established to allow patients to be treated locally.

Because of the successful partnership with DHR, the CTRC added several other virtual tumor boards with facilities in Laredo and Harlingen. Additional virtual tumor boards are also being planned for other parts of South Texas regions that lack extensive multidisciplinary care and require long distances for patients to travel for such care. In addition to the virtual tumor board with DHR, the CTRC has developed a clinical affiliation agreement that allows clinical trials to be offered at DHR.

The CTRC takes its mission to serve all of South Texas very seriously. To address the challenge of reaching patients within its surrounding 38 counties and throughout South Texas, the CTRC’s ultimate goal is to provide a comprehensive network of virtual tumor boards across the entire South Texas region.


WHAT DOES THE CTRC

MEAN TO YOU?This past fall we placed notecards and pens at various sites throughout our CTRC facility asking our patients to anonymously write and leave an answer to the question “What does the CTRC mean to you?” What they left us was a gift far greater than we could ever have imagined. Their sentiments touched our hearts and filled us with so much pride that we felt compelled to share them with you. The word cloud on this page and the quotes found throughout this report represent some of the many responses we received.

Their voices bring hope to all those diagnosed with cancer, and encouragement to our physicians, nurses, scientists and staff who continue to persevere in the fight against cancer for all our patients and their families.


“When I found out that I had prostate cancer, my family and I didn’t want to run from it. We wanted to go ahead and face it and go on with life. My doctor in Austin said I had to go see the very best, Dr. Ian Thompson at the CTRC. He was so right. Dr. Thompson is a terrific human being, physician and surgeon. He was like a great quarterback in a game! He was so ready to get me started and ‘put me in the game’ and everything turned out exactly like he said it would.”

Coach Fred AkersThe University of Texas at Austin

VOICES OF VICTORY OVER CANCER

“We say you don’t go back to being the same person after cancer, and it takes time to work through the emotional journey after the physical cancer is gone. I now volunteer at the CTRC and stay involved. Why? Because I want to experience the highs and lows and always remember that each day is a blessing. My heart overflows when I witness my fellow cancer survivors conquer their fears. My life is enriched to experience the genuine care and concern on each other’s behalf and the needs of our new group members.”

Vicki Shapirocancer survivor and former CTRC patient

“As a patient, the National Cancer Institute (NCI) designation is essential to the location you choose to receive help for cancer. When I was diagnosed with cancer, I was really frightened and I needed to know that I was going to be treated by the best doctors. I am grateful that I was able to be treated at the CTRC, [this region’s only NCI-designated cancer center] by so many wonderful doctors. And, I was able to be treated in San Antonio, my home.”

Phyllis BrowningUT Health Science Center Development Board Chair

Phyllis Browning with her husband, Jamie Browning.

Coach Fred Akers (seated left in white shirt) reminisces with members of his extended family.

Vicki Shapiro


Divider Page Education and Training

EDUCATION AND TRAINING

Excellent medical care.

Wonderful people.

“ “


CULTIVATING CURIOSITY IN CANCER RESEARCHThe Cancer Therapy & Research Center’s (CTRC) Oncology Research Internship (ORI) program, heading into its third year, is revealing to a growing body of young scientists-to-be that cancer research and care require and generate inspiration.

Ten young people spent four weeks soaking up experience in research, patient care, regulatory affairs, labs and professional development discussions, while thrilling their hosts in the process.

“I’ve had second-year medical students who didn’t ask such deep questions,” said Claudia Espitia, a researcher at the CTRC’s Institute for Drug Development (IDD). “They were an amazing group.”

During her time with the interns, who ranged from high school to undergraduate college students, Espitia guided them through basic techniques of molecular biology and showed them the lines of cancer cells with which she works. She showed them how to count cells, isolate DNA and amplify genes.

While they delved into several areas, the interns also looked at areas that were of individual interest.

Health Careers High School graduate Andrea Gomez plans a career in plastic surgery, knowing she might be involved in reconstructive surgery on cancer survivors. Gomez said she decided the ORI program could broaden her perspective. After observing in the CTRC’s Plastic and Reconstructive Surgery Clinic, Gomez said, “It made me value life.”

Michelle Chen, another Health Careers graduate, said, “I got to shadow two doctors and they taught me so much. This internship taught me about medical skills, but also job skills. It really has multiple benefits.”

The interns also enjoyed rotating through the pharmacokinetics (PK) department to learn about certification required of anyone who prepares hazardous materials.

EDUCATION AND TRAINING

Chen said her mother was concerned that a career in oncology treating very ill patients might be emotionally challenging.

But Chen found that may have been her favorite part.

“Everyone was super sweet and dedicated,” she said. “I’ve never met a group of people more full of life than I did this summer at the CTRC.”

Local youth soaked up experiences in scientific research, patient care and professional development as participants in the CTRC’s Oncology Research Internship program. The aspiring scientists came from high schools and undergraduate colleges throughout the city.


$1.4 MILLION FROM NCI HELPS TRAIN RESEARCHERSLatinos historically are underrepresented in careers in science and health care. But with the Latino population swiftly growing nationwide, more Latino health care workers and

scientists are needed to address the population’s equally growing health care needs. Deadly diseases such as cancer, for example, have surpassed heart disease as the No. 1 killer of Latinos.

Thanks to the successful work of UT Health Science Center San Antonio researcher Amelie Ramirez, Dr.P.H., director of the university’s Institute for Health Promotion Research and CTRC associate director for Cancer Prevention and Health Disparities, the Health Science Center has recently received an additional $1.4 million in funding from the National Cancer Institute (NCI) to continue through the year 2010, her R25 training grant “¡Exito! Latino Cancer Research Leadership Training program.”

¡Exito! features a summer institute, internships and other activities that encourage Hispanic master’s degree-level students and master’s degree-trained health professionals to pursue a doctoral degree and careers in Latino cancer control research.

To date, 101 individuals have graduated from the ¡Exito! program. Of those, more than 35 percent have applied to doctoral programs and more than 25 percent are currently enrolled in a doctoral program.

CTRC TEAM EDUCATION AND TRAINING

PARTNERSHIP PRODUCES BIOINFORMATICS DATA PROS The Cancer Bioinformatics Initiative: A UT Health Science Center San Antonio/University of Texas at San Antonio (UTSA) Partnership is an inter-institutional effort to support state-of-the-art training in computational biology and bioinformatics in San Antonio. Robin Leach, Ph.D., a professor of cellular and structural biology at the UT Health Science Center, assembled an experienced group of faculty to develop a unique educational training program in

bioinformatics and computational biology with an emphasis on the needs of the cancer research community.

“This program provides opportunities for students and faculty at UTSA, which is a minority-serving institution, to gain relevant experience by interacting directly with cancer center members at the Cancer Therapy & Research Center (CTRC),” Dr. Leach (pictured) said.

“The interaction also provides Health Science Center cancer researchers with needed computational analysis and modeling assistance from quantitative scientists across both campuses,” she said.

Additional opportunities are provided for intensive short courses/workshops and practicums for computational biology training aimed for a mixed audience of biologists and quantitative scientists.

Pictured are ¡Exito! program participants, program leaders and staff.

A participant describes his project during a recent ¡Exito! Summer Institute, an annual part of the ¡Exito! program offered to master’s-level students and professionals.


PROTOTYPE FOR PROGRESS As a renowned cancer center that serves patients and develops new cancer drugs, the Cancer Therapy & Research Center (CTRC) has the opportunity to train talented hematologists and medical oncologists from around the globe. The Advanced Oncology/Hematology Drug Development Fellowship Program, established at the CTRC in the late 1980s and operated through the CTRC’s Institute for Drug Development (IDD), offers oncologists a chance to work closely in the development of new cancer treatments.

GRADUATE PROGRAM OFFERS CUTTING-EDGE TRAININGThe Integrated Biomedical Science (IBMS) Graduate Program, which replaces the previous graduate program, the Integrated Multidisciplinary Graduate Program (IMGP), reflects contemporary interdisciplinary advanced education and scientific research based on fundamental principles in the biomedical sciences. Students are enrolled in the IBMS rather than in individual, discipline-based doctoral programs. The IBMS, currently composed of seven disciplines, including the Cancer Biology discipline, addresses the most significant training areas in biomedicine. These thematic disciplines have been aligned with the major research foci of the faculty in the institution. Cancer Biology is the largest theme in the graduate program with 21 graduate students in three basic and three clinical departments engaged in various cutting-edge dissertation projects that span basic, clinical and translational cancer research in the laboratories of faculty members with full CTRC affiliation.

The Cancer Biology discipline/track is led by CTRC members, Alexander Pertsemlidis, Ph.D., and Babatunde Oyajobi, M.D., Ph.D. In addition to Drs. Oyajobi and Pertsemlidis, other CTRC faculty members have also taken on discipline leadership roles.

Two research training grants directed by CTRC members support Cancer Biology students in the graduate program. One is funded by the National Institutes of Health (NIH)/ National Cancer Institute (NCI) and is the institutional Ruth Kirschtein T32 Training Award. The PI is Dr. LuZhe Sun. The other is funded by the Cancer Prevention & Research Institute of Texas (CPRIT) and is the Cancer Research Training Award. The PI is Dr. Oyajobi.

CTRC TEAM EDUCATION AND TRAINING

Steve Weitman, M.D., Ph.D., said the Advanced Oncology/Hematology Drug Development Fellowship Program continues to be one of the CTRC’s most important programs.

“It continues to establish our worldwide footprint,” Dr. Weitman said.

Laeeq Malik, M.D., completed his fellowship in early 2015 and returned to his homeland of Australia. Alex Mejia, M.D., of the Dominican Republic, completed his fellowship in August and joined the faculty of the CTRC.

“During the IDD fellowship I learned how to put together the current concepts of drug development in oncology under the perspectives of regulatory agencies,” Dr. Mejia said. “It’s not only an intangible badge of accomplishment, but also provides everyday clinical practical skills that guide my professional life on offering the most contemporary treatments.

The newest IDD fellows who joined the program in 2015 include Josephine A. Taverna, M.D., of Guadalajara, Mexico, and Sarunas Sliesoraitis, D.O., Pharm.D., of Kaunas, Lithuania.

Pictured (left to right) are Drs. Laeeq Malik, Steve Weitman and Alex Mejia.


COMMUNITY IMPACT

The CTRC means family, hope, faith

and being there with you all the way;

not letting you give up; everything is going

to be fine; seeing you through it all, side by side.

““

Author Jason Gay (center) signs copies of his book “Little Victories: Perfect Rules for Imperfect Living”

for eager attendees at the 2015 San Antonio Express-News Book & Author Luncheon as event volunteer Becky Smith (left) and event committee member/volunteer Anne Ownby look on.


P ioneer. Adventurer. Trendsetter. These are the words that Bebe Bowen’s family and friends use to describe her. That’s because Bowen takes pride in being a leader in everything she does.

After graduating with her bachelor’s degree from the University of Tennessee, Bowen joined American Airlines in 1946. Soon, she was a member of the first class of flight attendants to graduate from the Ardmore Training Center in Oklahoma in 1947.

In her 30 years with American Airlines, Bowen served as a flight attendant aboard every airplane in the airline’s fleet from the DC-3 to the Boeing 747 – except the Lockheed Electra. She also volunteered to help staff American Airlines flights for the Military Airlift Command (MAC) during the Vietnam War. After a long and exciting career with American, she married William H. Bowen in September 1975 and retired in 1976 in Dallas, Fort Worth. She was the first flight attendant to do so from that particular base.

“I wouldn’t have traded it for anything,” Bowen said. “I met so many wonderful people and lived in different places. It was a great opportunity and I was thrilled,” she said.

In her tradition of firsts and with her passion for touching people’s lives across the globe, Bowen also takes pride in being a primary supporter of causes that make a difference in people’s lives across the world. That’s why early on she chose to support The Cancer Therapy & Research Center (CTRC) at the UT Health Science Center at San Antonio.

In 2013, Bowen became the first CTRC Cabinet member to make a Cabinet gift at the $100,000 level. She joined the dedicated group of CTRC friends who support the CTRC with annual gifts of $1,000 or more every year. Now, in her retirement and living in Dallas and Indian Wells, Calif., Bowen continues to support the CTRC Cabinet at this level.

“We cannot thank Bebe enough for her incredible gifts to support our work at the CTRC,” said Ian M. Thompson Jr., M.D., director of the CTRC.

“I am honored that Bebe selected the CTRC to mark another first in her life and ours. It is a privilege to recognize her for the many accomplishments throughout her life and to thank her for her support of the CTRC,” Dr. Thompson said. “Her generous gifts will touch the lives of cancer patients across the globe just as she touched so many lives in her travels and years of service.”

Bowen Blazes trail for CtrC’s future

(Right) Bebe Bowen in the late 1940s.

(Below) Bebe Bowen’s first flight as a flight attendant was aboard the Flagship Knoxville. Now on permanent display in the American Airlines C.R. Smith Museum in Fort Worth, Texas, the iconic DC-3 airplane is the centerpiece of the museum as it revolutionized commercial air travel in the 1940s.


Honored and humbled are the words Kathy Ashwin uses to describe how she and her husband, David, felt when H-E-B, one of

the largest independently owned food retailers in the nation, established the Kathy and David Ashwin Endowment

for Medical Research in their honor at The University of Texas Health Science Center at San Antonio. H-E-B representatives

surprised Kathy when they announced a gift of $250,000 in recognition of her many years of dedicated service to the

company and the H-E-B Tournament of Champions. The annual golf tournament fundraiser was initiated by Kathy and her boss at

H-E-B 30 years ago, and, to date, has raised more than $80 million for children and education in Texas.

“When H-E-B honored us in this way, we wanted the endowment to help advance promising medical research that was really needed,

especially for bright, young scientists with the drive and expertise to see a new way to prevent, treat or cure patients with serious health

conditions like our family had faced at that particular time.”

Kathy and David had just learned David had developed stage 3 lung cancer, and they were hoping the doctors at the CTRC could help.

“Lung cancer is one of the most prevalent cancers in Texas,” Kathy said. “Many people face the challenges every day, and often, like Dave, have other health conditions that make their treatment more challenging.”

David had received medical care in the past from physicians of UT Medicine San Antonio, the clinical practice of the

School of Medicine at the UT Health Science Center. Because the Cancer Therapy & Research Center, San

Antonio’s and the South Texas region’s only NCI-designated cancer center, is a part of UT Medicine

San Antonio, Kathy and David knew his care

could be coordinated by UT Health Science Center doctors, nurses and staff from the very beginning.

The initial assessment of David’s cancer was not hopeful. His lung cancer was so aggressive that his chance of survival was only about 8 percent. CTRC physicians determined David was healthy enough to tolerate the highest dosage of standard-of-care chemotherapy and followed it with 33 radiation treatments.

Six months after diagnosis, the scans showed no cancer. But the likelihood of recurrence was high, so the next step was to offer David a clinical trial at the CTRC – a new, experimental vaccine that could prevent the cancer from coming back.

“The empathy of the doctors, nurses and staff at the CTRC provided a family environment to facilitate my cancer treatment so it didn’t feel like a treatment facility,” David said. “I knew they had my best interest at heart because they took care of us like family.”

David progressed well and remained cancer free, but he was also dealing with other health matters. He began to experience fluid build-up in his heart and lungs. He was in the hospital for 25 days, but made a full recovery. “I cannot say enough about the quality of care that Dave has received at the CTRC and UT Medicine over the years,” Kathy said. “The compassion and knowledge of all the physicians, nurses and staff is like nothing I have ever

CHAMPIONS OF EDUCATION, RESEARCH AND CARE


experienced. They have saved his life more than once, and they gave our family the gift of having him with us to share so many important family milestones.”

Woondong Jeong, M.D., continues to see David regularly at the CTRC for his ongoing care and check-ups. Dr. Jeong is assistant professor of thoracic, head and neck oncology at the CTRC and also oversees Phase 1 clinical trials.

“We admire Dr. Jeong because his life is truly dedicated to helping patients like me who are fighting the scourge of cancer,” David said. “When we learned the story of how he came to the CTRC, Kathy and I were truly moved. Dr. Jeong grew up in South Korea. He taught himself English and had to leave his family and his home to pursue his dreams of making a difference in the fight against cancer in the United States,” David said.

David said he was impressed by how Dr. Jeong sacrificed, worked hard and secured a prestigious position at the NCI, and was determined to work in the CTRC’s Phase 1 clinical trials program.

“Dr. Jeong’s life has been driven by his dedication to cancer research and helping his patients,” David said. He is not only a brilliant physician and scientist, but he also has the compassion and drive to find cures for cancer.”

Dr. Jeong is also the inaugural holder of the Kathy and David Ashwin Endowment for Medical Research.

“I never expected to have an endowment for many years, so I am deeply honored to have been appointed to the Ashwin endowment,” Dr. Jeong said. “I am committed every day to

doing my best to advance research that will help patients like David Ashwin and so many others here who are counting on us to offer them new hope,” he said.

David holds two doctoral degrees, one in theology and the other in philosophy. He had always been healthy and active. Even after being diagnosed with diabetes in 2004, it was hard to keep David down. He was raised in upstate New York where he began the fifth Southern Baptist Church in New York State. He is an ordained minister and a former elementary school teacher. Family and friends say his faith is a vital factor in his day-to-day living, and his life exemplifies his care for others.

Kathy grew up in Aransas Pass, Texas, and studied secretarial science at Texas A&I University in Kingsville. She worked for

H-E-B for 25 years and has continued to serve as the director of the H-E-B Tournament of Champions for 30 years.

“H-E-B’s commitment to their employees and to the communities they serve is a model for excellence,” Kathy said.

“Dave and I are very proud that Dr. Jeong is the holder of the Ashwin Endowment, which will help to advance his cancer research. We are so pleased that this endowment will have significant impact long after we are gone,” Kathy said. “H-E-B’s generosity to do this meant the world to both of us, and their gift, in our name, will live on and continue to support breakthroughs in medical research for generations to come. It is a legacy to make lives better that we never could have imagined.”

(Above) Alain Mita, M.D. (left), who was among Dr. David Ashwin’s physicians at the CTRC, is greeted with a hug from Kathy and David Ashwin.

(Left) Dr. Woondong Jeong


GREETINGS FROM THE CTRC BOARD OF GOVERNORS

On behalf of the entire Cancer Therapy & Research Center (CTRC) Board of Governors, I thank you for your generous and steadfast support of our CTRC. It is my privilege to lead the extraordinary group of business and community leaders who come together as board members in support of the CTRC. Our board provides support to the CTRC by acting as ambassadors for the cancer center in the community; supporting key recruitments and strategic priorities; providing the CTRC leadership with critical feedback; contributing to the CTRC philanthropically; and cultivating Cabinet level supporters.

Over the last 41 years, our National Cancer Institute (NCI)-designated CTRC has grown in its scope and size to serve an ever-increasing number of patients. Yet, its mission has remained the same – to provide cutting-edge, lifesaving therapies to its patients, all the while focusing on the well-being of the patient. From the researchers in our Institute for Drug Development (IDD) to the volunteers in our Wellness Center, the patient is the top priority at the CTRC. The CTRC provides comprehensive cancer care for patients – from the development of new drugs; to recruitment of top clinicians and researchers; to the acquisition of the latest therapeutic tools; to the maximizing of the patient experience through multi-disciplinary care teams; and to the outreach programs for patients.

It is easy to give so generously of our time and talents to the CTRC because it is so worthy of our support. Under Dr. Ian Thompson’s dynamic leadership, the CTRC continues to achieve even greater levels of excellence. The physicians, scientists and staff make meaningful strides every day in the fight against cancer, and your partnership – through your vote of confidence in the CTRC and your financial contributions – make the important work of the CTRC possible.

Thank you for the part you play in supporting the mission of the CTRC.

Together, we make lives better.

Karen Lee Zachry Chair, CTRC Board of Governors

BOARD OF GOVERNORS 2015-2016

Board members Mike Birnbaum and Beverly Birnbaum

Board members Margie Klesse and Jan Newton

Board members Marty Wender and Edith McAllister


Karen Lee Zachry, ChairLori Wright, Chair-Elect

Christine D. AldereteWayne AlexanderErnesto AnciraYolanda AndersonDr. Forrest Aven Emerson Banack, Jr.Rose Marie BanackLouise D. BeldonMichael D. BeldonMichael BelzBeverly A. BirnbaumMichael L. BirnbaumStanley L. BlendDonna BlockMary Ballenger BrookSteven R. BrookJamie BrowningJ. Bruce Bugg, Jr.Pam BurdickT. Randall CainJim CallawayDya C. CamposAlonzo CantuCharles E. CantuChaCha CavazosCharles E. CheeverJean CheeverGraciela CigarroaLisa H. CohickDr. Elizabeth ConklynLouis R. CooperBob CowanLynn Finesilver CrystalDr. Suzanne Marlar DabbousJ. Russell Davis

Laura DixonTom DobsonBarbara B. DreebenGerald Z. DubinskiStephen M. DufilhoArthur EmersonHelen EversbergBrian FeldRenee FloresDr. Kelley FrostPatrick B. FrostSteven W. GarzaLeo GomezJames W. GormanJames GreenwoodRhonda GurinskyRobert E. GurwitzKenneth J. HallidayPatricia HayesRoxana C. HayneChristine L. HaynesJoe N. HaynesKaren L. HeintzRoger R. HemminghausF. Peter HerffKaren H. HerrmannCari S. HillJanet HollidayKaye D. HoltLinda HummelRobert L. JemersonKathryn Mays JohnsonLaurie A. KaplanJohn L. KauthEdward B. KelleyNancy L. KelleyMargie KlesseEdward K. Kopplow

John C. KorbellCarolyn LabattMilton B. LeeAndreae LeMaistreDr. Charles A. LeMaistreMolly LightNancy LoefflerJeff LottKatie LuberMike ManuppelliJaney Briscoe MarmionTracie MartinEdith S. McAllisterTaddy McAllisterWalter W. McAllisterDavid P. McGeeJoe C. McKinneySherry McNeilDr. Thomas M. McNishYona McNishMark MeadorBalous T. MillerLou MillerDebbie MontfordJennifer MoriartyKaren Norman MuellerLee MuellerTim MusgraveTerrie E. MusselmanDr. Dacia H. NapierJan NewtonPhil NormanMichael J. NovakMargie K. O’KrentSam O’KrentJudy PalansCamilla M. ParkerDonna M. Pasacrita

Phil PfeifferJane Cheever PowellDuane C. PozzaDr. Carl F. Raba, Jr.Thomas R. RansdellJack C. RichmondAndrea F. RodriguezRobert A. RosenthalShawn RosenzweigLouis E. RoweDianna RoyJane R. SatelDona SchenkerRichard T. SchlosbergLisa M. SechlerStephen D. SeidelC. Frederick ShannonDeeAnn SimpsonDr. Gurvinder P. SinghJames B. SmithDennis W. StahlHarris J. SterlingRuth Eilene SullivanNancy TorgersonVernon TorgersonMary West TraylorJon TurnerW. Lawrence WalkerAnaPaula WatsonMark E. Watson, Jr.Lora WattsVirginia WelderCharles Martin WenderKenneth L. WilsonMertie WoodGary V. WoodsMark H. WrightLois F. Yancy

2015-2016 BOARD OF GOVERNORS

Mark E. Watson, Jr., Dr. Ian Thompson, Gary Woods and Pat Frost

Rose Marie and Buddy Banack

Dennis Stahl, Mike Beldon and Mark Wright


Judy Palans Tom Ransdell W. Lawrence Walker Jr. Mark E. Watson Jr. Gary V. Woods

COMMUNITY LEADERSHIP AND SUPPORT YEAR IN REVIEW

GREETINGS FROM THE CTRC FOUNDATIONThe CTRC Foundation was founded in 1991 as the CTRC Endowment Corporation with initial funding of $50,000 provided by the late Dr. Burton Grossman. Since that time, the endowment has increased substantially, with the largest funding to date totaling $85,000,000 from the sale of Ilex Oncology shares in 2005.

The CTRC Endowment Corporation became the CTRC Foundation following the merger of the CTRC with the UT Health Science Center in 2007. Over the past seven years, the Foundation

has contributed approximately $45 million to support the CTRC. The Foundation’s current endowment balance is $45 million.

Currently, the CTRC Foundation consists of 10 board members:

Louise Beldon Jim Callaway Barbara Dreeben James W. Gorman Jr. John Kauth

The board meets quarterly to review investments and consider funding requests from the CTRC for the continuation of endeavors aimed at fulfilling the primary mission of the institution – to serve the people of Central and South Texas by advancing cancer research, treatment, prevention and education.

As chairman of the CTRC Foundation Board, I proudly share in the continued commitment of our members to serve as stewards of this endowment fund for the future of our community.

Gary Woods Chair, CTRC Foundation Board

GREETINGS FROM THE CTRC COUNCILThe CTRC Council continues as it began 31 years ago, as an all-volunteer organization dedicated to supporting the extraordinary work of the CTRC. Our commitment comes in three key areas: fundraising, volunteer efforts and educational outreach.

By the end of 2015, the Council’s accumulated donations will exceed $4.3 million. In addition to our Annual Spring Luncheon, Partners Shopping Card, the Big Give and other events, the CTRC Council is a key partner in the San Antonio Express-News Book & Author Luncheon. The money we

raise goes to fund breakthrough research to prevent and cure cancer, and to care for patients struggling in their personal battle against cancer.

To continuously expand our support of the CTRC, existing fundraising events have grown over the years, and additional events continue to be added. This year, we introduced the “Circles of Hope” program in which a group of 10 donors can come together to select and fund a critical pilot research project, with 100 percent of the money allocated directly to the project to advance the research.

With more than 700 members, we are able to keep the CTRC food pantry stocked, offer ongoing patient assistance, and provide thousands of volunteer hours including help with registration at the largest Breast Cancer Symposium in the world, which takes place in San Antonio every year. And the list goes on.

Recently, our Board of Trustees voted to create dedicated Marketing and Social Media Committees for 2016. This will greatly enhance our ability to spread the word about the CTRC, which is an amazing resource for our community.

We are constantly inspired by the excellence and compassion of the CTRC physicians, scientists, nurses and staff. We are honored to have been a partner for three decades, and enthusiastic about all that is still to come!

Liz Conklyn President, CTRC Council


MAJOR GIFT HIGHLIGHTSYEAR IN REVIEW

$5 MILLION GIFT FROM MAYS FAMILY ESTABLISHES DISTINGUISHED UNIVERSITY PRESIDENTIAL CHAIR

Each year, nearly 14 million people learn they have cancer and 8 million die from the disease worldwide. The U.S. Centers for Disease Control and Prevention reports that one-third of cancer deaths can be prevented. For some patients, especially those living in low- and middle-income regions, treatment services and technologies are not widely available to help them.

Peggy and Lowry Mays know firsthand that cancer does not discriminate. Both have survived a cancer diagnosis. “Cancer can strike anyone at any age, no matter who you are or where you’re from,” Lowry Mays said. “We need exceptional resources right here in Texas.” That’s why the San Antonio couple has made it their mission to ensure that other Texans have a fighting chance against the disease.

The Mays have been steadfast supporters of the CTRC for decades. In 2015, together with their family, they made a $5 million gift to establish an endowment – the Mays Family Foundation Distinguished University Presidential Chair for the Director of the CTRC. Dr. Ian M. Thompson Jr., CTRC director, is the holder of this prestigious academic chair.

“Everyone deserves access to the utmost cancer treatment and care,” Lowry Mays said. “Peggy and I felt this was a turning point in the CTRC’s history and an important time in the CTRC’s history to further invest in an already exceptional institution where the focus is on cancers that most affect the citizens of this region. Our community deserves the best.”

In an age of diminishing funding for scientific research, the Mays Family Foundation endowment will support important programs such as pilot research projects, faculty recruitment and retention, clinical trials, new technology and cancer prevention. The gift also honors the 40th anniversary of the establishment of the CTRC in San Antonio and the 24 years that it has merited distinction as this region’s only National Cancer Institute (NCI) designated cancer center.

“This endowment is an extraordinary gift that will fuel opportunities for scientific breakthroughs and invest in the best and brightest minds in cancer research,” said William L. Henrich, M.D., MACP, president of the

UT Health Science Center. “It is a remarkable testament to the Mays’ continuing commitment to the community and to the important role the CTRC has played herein.”

Dr. Thompson describes Peggy and Lowry Mays as dedicated friends and community leaders who are passionate about eliminating cancer. In 1996, Peggy Mays helped organize and create the CTRC Cabinet, a group of committed donors who contribute $1,000 or more annually to the CTRC to fund the center’s highest priority needs in cancer research and treatment.

“Peggy and Lowry not only helped guide us from the beginning, they have committed to helping us over the years to reach ever-higher standards of excellence. They planted a seed that has grown into a full tree,” Dr. Thompson said. “Now they are planting again, and thanks to their generosity and leadership, our community will benefit from the excellence we harvest.”

“I have always felt like the CTRC was my ‘baby,’ and I am exceptionally proud of the remarkable progress our talented physicians, scientists, nurses and staff have made over the years,” Peggy Mays said. “Lowry and I and our entire family are delighted to honor the CTRC for its 40 years of life-changing work and to support its aspirations for the future.”

The Mays Family Foundation, formed in 1994, is committed to supporting the community through causes that empower, enrich and educate. As a family, pictured here with Dr. Ian Thompson (far left) and UT Health Science Center President William L. Henrich, M.D., MACP (far right), they have contributed more than $55 million to the communities in which the family lives and works.


WELLS FAMILY MAKES $1 MILLION GIFT — THIRD CONSECUTIVE YEAR Jodi and Richard Wells and their family have once again donated an unrestricted $1 million cash gift to the CTRC to support the efforts of Ian M. Thompson Jr., M.D., CTRC director, and his talented team of physicians, scientists, nurses and staff at the cancer center. Mr. and Mrs. Wells said they strongly believe in the exceptional work and advances at the CTRC that they intend to make an annual $1 million gift to the CTRC for as long as they are able.

“The remarkable generosity and support of the Wells Family enables me to retain and recruit the best and brightest talent to the CTRC; invest in the most promising cancer research; and advance innovative new cancer therapies in our efforts to find the cancer cures of tomorrow,” Dr. Thompson said.

Mr. Wells said their support of the CTRC was inspired and meaningful to them.

“We are incredibly honored and proud to be able to help Dr. Thompson and his team,” Mr. Wells said. “I lost my father, Robert Milford Wells, to lung cancer in 2010, and my family and I make these gifts in his loving memory with the hope that we are doing our part to help eradicate cancer in our lifetime,” he said.

CTRC COUNCIL REACHES $4.3 MILLION CONTRIBUTION MILESTONE The CTRC Council, founded in 1984, is a volunteer non-profit organization whose mission is to support the Cancer Therapy & Research Center (CTRC) through fundraising, community outreach and education, patient assistance and volunteer services. With more than 700 members, the Council has raised $4.3 million over the past 31 years to support the CTRC’s important programs, compassionate patient care and breakthroughs in cancer research and drug development.

CTRC Council President, Liz Conklyn, and the Council’s Board of Trustees are extremely proud of their partnership with the CTRC. The members of the Council work tirelessly to raise vital funds for the cancer center. Their dedication, commitment and hard work have resulted in many milestones including:

MAJOR GIFT HIGHLIGHTS YEAR IN REVIEW

• $1,000,000 donation to name the CTRC Council Radiation Therapy area in the CTRC

• $750,000 to establish the CTRC Council Patient Education Suite in the CTRC Breast Cancer Clinic

• $1,000,000 to establish the CTRC Council Distinguished Chair in Oncology at the CTRC

• $600,000 to support the CTRC Patient Assistance Fund

•` $275,000 to provide important cancer research grants

• $250,000 to support capital improvements

• $240,000 to purchase state-of-the art equipment

• $100,000 to support pilot research projects at the CTRC (seed funding for physician scientists to advance their cutting-edge cancer research)

• $63,000 to purchase two new vans to provide free transportation for CTRC patients to receive their lifesaving treatments

This past year, the CTRC Council initiated several new projects, such as the Circle of Hope Program, to help increase its support and reach greater heights in its quest to make a profound impact in the fight against cancer.

Circle of Hope gathering


MAJOR GIFT HIGHLIGHTSYEAR IN REVIEW

CTRC CABINET TOPS $7 MILLION TO CELEBRATE ITS 20TH YEAR

The CTRC Cabinet was founded in 1996 to provide essential annual funding to support the important programs of the CTRC. The Cabinet is comprised of dedicated donors, supporters, community leaders and businesses who contribute $1,000 or more annually to the CTRC.

Last year, under the exceptional leadership of Cabinet Co-Chairs, Lori Wright and Karen Heintz, the CTRC surpassed 200 Cabinet members and raised $699,000 in Cabinet gifts. This year, Wright and Heintz set a goal of $750,000 and report that they are on track to meet or exceed their target by the year’s end. This will bring the cumulative total of CTRC Cabinet gifts to $7 million.

“The Cabinet funds support the lifesaving work of the CTRC’s Institute for Drug Development (IDD) where researchers push the frontier of cancer research through innovation and discovery,” said Ian Thompson, M.D., CTRC director.

“This vital support is invaluable in helping to develop new, more effective cancer therapies for our patients,” he said.

COMMUNITY FUNDRAISERS RAISE VITAL SUPPORT FOR THE CTRC The faculty and staff of the CTRC are deeply grateful to the numerous community fundraisers each year that support its endeavors. Through the hard work and dedication of countless community leaders and volunteers, critical funding is raised to support cancer research, patient assistance and programs. Some of those events include the following:

CTRC Council Spring Luncheon

The CTRC Council Annual Spring Luncheon is well-known as a “crowd-pleaser.” This year’s dynamic speaker was Geralyn Lucas, author of the book “Why I Wore Lipstick to My Mastectomy.” At the luncheon, Lucas told her compelling personal story of how she battled breast cancer. She had the sold-out audience in tears one moment, and laughing out loud the next. The Council raised $83,000 through this fundraiser this year to support the CTRC Patient Assistance Fund. The program helps needy CTRC cancer patients and their families with transportation, lodging, nutritional supplements and many other services.

CTRC Council Partners Shopping Card

The Partners Shopping Card is always a major hit with the community. This year marked its 16th anniversary. More than $2 million was raised since its inception including $900,000 to support the CTRC Council Distinguished Chair in Oncology, held by Michael Wargovich, Ph.D., co-leader of the CTRC Cancer Prevention and Population Science Program. The card provides a 20 percent discount at more than 350 participating retailers and restaurants during the 10-day shopping period in October.

San Antonio Express-News Book & Author Luncheon

In its 24th year, the San Antonio Express-News Book & Author Luncheon has raised more than $3.5 million to benefit the Phase 1 Clinical Research Program at the CTRC. Six prominent authors and their latest books are featured at the luncheon to a sold-out audience of more than 1,000 attendees each year. The authors discuss their books and experiences and luncheon guests may purchase their books and have them autographed by the authors.

LUNCHEONS P R I N G

CTRC COUNCIL

Dr. Ian Thompson Jr. (center) thanks (L-R) event Co-chair Dr. Virginia Kaklamani, Committee member Lora Watts, and Co-chairs Jan Newton and Mary Brook at the 2015 San Antonio Express News Book & Author Luncheon.


Saks Key to the Cure

Saks Fifth Avenue San Antonio selected the CTRC Breast Cancer Program as the beneficiary of its Key to the Cure fundraiser for the seventh consecutive year. Saks donates 100 percent of the sales from the Key to the Cure designer T-shirts and 2 percent of all store sales during the four-day Friends and Family shopping days in October from its North Star Mall location. Saks has donated more than $117,000 to the CTRC over the past seven years.

Vulcan Materials Company Golf FUNdraiser

Pictured (L-R) Ed Mueller and Mark Wright team up and tee it up at the first Vulcan Materials Company Golf FUNdraiser held Oct. 19 at the TPC San Antonio, on the grounds of the JW Marriott San Antonio Hill Country Resort and Spa. More than 250 participated in the inaugural tournament raising more than $67,000 to benefit programs at the CTRC.

H-E-B Beauty of Giving

Representatives from H-E-B (pictured above) presented a check in the amount of $55,000 to the CTRC to support its Breast Cancer Program. In honor of Breast Cancer Awareness Month, H-E-B administrators joined with their team of beauty advisers during October to help raise funds for the CTRC. Their efforts paid off through an in-store promotion in which a portion of the sales from a variety of beauty and general merchandise items benefited the CTRC Breast Cancer Program. The beauty advisers also pampered four CTRC breast cancer patients with custom beauty makeovers at the H-E-B Plus! in-store beauty salon on Highway 281 and Evans Road.

City of Schertz Wilenchik Walk for Life

The City of Schertz donates 100 percent of the net proceeds from its annual Wilenchik Walk for Life to support the CTRC’s Institute for Drug Development (IDD) in memory of Tony Wilenchik, its beloved city councilman who lost his battle with cancer in 2009. Wilenchik was a Phase 1 patient at the CTRC. His wife, Valerie, said she is proud that the city of Schertz continues to honor her husband’s memory through this event. More than $150,000 has been raised from the Wilenchik Walk to support the IDD.

MAJOR GIFT HIGHLIGHTS YEAR IN REVIEW

Dr. Ian M. Thompson (right) presents the Saks Key to the Cure Award to Dr. Virginia Kaklamani (center) in recognition of her outstanding commitment as a CTRC physician and researcher. Dennis Trammell, Saks general manager, stands by on stage to congratulate her.


2015 CTRC CASH DONATIONS, PLEDGES AND BEQUESTS AS OF OCTOBER 31, 2015

MAJOR GIFTS

Mays Family FoundationCTRC FoundationJodi and Richard Wells

CTRC 40TH ANNIVERSARY ENDOWMENT

Visionary’s Circle - ($50,000 +)Valerie and Jack Guenther

Patron’s Circle - ($20,000 +)Dolores and Jack Willome

Leadership Circle - ($10,000 +)Barbara and Alan DreebenNancy and Harvey NajimKathey K. and Robert A. AndersonPatty and Bob HayesTena and Jim GormanCourtney and Mark E. Watson, Jr.Linda and Ed Whitacre, Jr.Lori and Mark Wright

Director’s Circle - ($5,000 +)Nancy and Charlie CheeverH-E-B / Charles C. ButtKaren L. HeintzMr. and Mrs. Freddy Randall HileyBonnie and John KorbellDiane and Phil PfeifferCarl F. Raba, Jr.Judy and Palmer MoeSan Antonio Medical FoundationDot and Roger HemminghausMr. and Mrs. Richard C. TraylorGary V. Woods

Sustainer’s Circle - ($2,500 +)Louise and Michael BeldonPam and Art Burdick

Barbara and Michael GentryNancy and Ed KelleyJudith R. LachmanDr. and Mrs. Charles A. LeMaistreEdith McAllisterKaren and Lee MuellerMr. and Mrs. William A. Parker, Sr.Mr. and Mrs. Patrick StehlingRuth Eilene Sullivan

Partner’s Circle - ($1,000 +)AHMSA International Inc.Ancira Enterprises, Inc.Dr. and Mrs. Forrest AvenDr. and Mrs. Clinton BaisdenBeverly and Mike BirnbaumDonna BlockPhyllis and Jamie BrowningPaula and Jim CallawayCharles E. CantuMr. and Mrs. James M. Cavender, IIITaliaferro CooperTerry and Russell DavisJune Marie DayMarilyn and Gerald Dubinski, Sr.Dr. and Mrs. Lawrence L. EspeyOlive Anne and Tres KlebergDr. Kelley L. Frost and Mr. Patrick B. FrostLavonne and David GarrisonRhonda and Charlie GurinskyNancy Ann B. LoefflerJaney Briscoe MarmionDr. and Mrs. Thomas M. McNishMr. and Mrs. Lewis Jefferson Moorman, IIIJudy and Seymour PalansAndrea F. RodriguezLauren and Robert StanleyAnn Barshop

Cynthia and Thomas SchluterFrancie and Harris SterlingSuzanne and Dick WadeLora and Jim WattsDr. and Mrs. James William Yancy

Friends - (under $1,000.00)Lynn Finesilver CrystalJeannie and Alvin FriedenAnne W. JohnstonBeverly A. KoehnSheri and Manny OrtizBen PlummerAmelie and David RamirezDeeAnn and Skinner SimpsonDonna and Ian Thompson, Jr.Teri L. WengleinArlene and Jim Wueste

CTRC CABINET

Impact Circle - ($100,000 +)Bebe Bowen

Visionary’s Circle - ($50,000 +)Jodi and Richard Wells

Patron’s Circle - ($20,000 +)Charles C. ButtMargie and Bill KlesseLori and Mark Wright

Leadership Circle - ($10,000 +)Checks In The Mail, Inc.Jean M. CheeverPatty and Bob HayesKaren L. HeintzRose Marie and John L. Hendry, IIINick McFadinKathy and Tim MusgraveDacia and Lanham Napier

Marion OppenheimerDolores and Jack WillomeGary V. Woods

Director’s Circle - ($5,000 +)Mr. and Mrs. Richard AcostaLexie and Rowan AltgeltMr. and Mrs. William D. BalthropePam and Art BurdickMr. and Mrs. Charles EbromKris and Jim EllisMr. and Mrs. Walter EmbreyThe Alfred S. Gage FoundationSandi and Bob KolitzMcClure Charitable FoundationMr. and Mrs. Sam MittsHarris K. & Lois G. Oppenheimer FoundationKathi and John OppenheimerCamilla and Bill ParkerCheryl and John SchoolfieldKaren Lee and David Zachry

Sustainer’s Circle - ($2,500 +)Judy and Jim AdamsDianne and Richard AzarBeverly and Mike BirnbaumMr. and Mrs. Charles E. Cheever, Jr.Dr. and Mrs. Francisco G. CigarroaMr. and Mrs. Eugene Dawson, Jr.Tena and Jim GormanSally HalffTina and Joe HaynesGail and Bob GurwitzNancy and Ed KelleyJan and Bob MarbutCarl F. Raba, Jr.Ann and Tom RansdellMr. and Mrs. Stanley D. RosenbergMr. and Mrs. Richard C. TraylorDr. Sandra and Mr. Dale Tremblay

COMMUNITY LEADERSHIP AND SUPPORTYEAR IN REVIEW


Partner’s Circle - ($1,000.00 +)Barb and Wayne AlexanderAnonymousJ. R. AvantAT&T/Renee FloresMr. and Mrs. Emerson Banack, Jr.Louise and Michael BeldonSusan and Brad BeldonAnn BiggsLinda and Stanley BlendDonna BlockMr. and Mrs. Michael BolnerMarrs McLean BowmanGeorge BranniesMary and Steve BrookMr. and Mrs. J. Bruce Bugg, Jr.Genie and Ron CalgaardPaula and Jim CallawayMr. and Mrs. Richard W. CalvertCharles E. CantuMr. and Mrs. Guillermo J. Cavazos, Jr.Judy and Jimmy CavenderMr. and Mrs. Richard H. CavenderChris CheeverMr. and Mrs. James Fully Clingman, Jr.Lisa and Don CohickMr. and Mrs. Robert L. Cook, Jr.Taliaferro CooperMr. and Mrs. Jack CopelandCharles L. Cotrell, PhDMr. and Mrs. Robert C. Cowan, Jr.Dr. and Mrs. Anatolio B. Cruz, Jr.Lynn Finesilver CrystalMr. and Mrs. Charles H. DavisTerry and Russell DavisMr. Luis A. De La Garza and Ms. Sherry Lynn HatcherJustice Preston H. Dial, Jr.Barbara and Alan DreebenMr. and Mrs. Gerald Z. Dubinski, Sr.Adele and Steve DufilhoMildred V. EhrenbergMr. and Mrs. Arthur Rojas EmersonMr. and Mrs. Louis ErdosEdith McAllister

Lawrence and Doina EspeyJimmie Ruth and Dick EvansSusan and Allen PierceMr. and Mrs. Brian FeldMr. and Mrs. Carl FellbaumMr. and Mrs. Israel FogielCaroline Alexander ForgasonDr. Kelley L. Frost and Mr. Patrick B. FrostMr. and Mrs. Eduardo GarzaBarbara and Michael GentryMr. and Mrs. Stephen GoebelDr. and Mrs. Roy R. Gonzales, Sr.Mr. and Mrs. Jaime D. GoodwinValerie and Jack GuentherMr. Cosmo F. GuidoDr. Glenn A. Halff and Ms. Mindi AltermanMarie M. HalffPatty and Ken HallidayRoxie and Jim HayneFrances Jordan HearnDot and Roger HemminghausLynn and Peter HennesseyDr. and Mrs. William L. HenrichMr. and Mrs. Frank Herrera, Jr.Karen and Ronald HerrmannJames HockstadtAnne Holt and C.D. SchultzMr. and Mrs. Leonard HolzmanReagan T. Houston, IVBillie-Kite HowlettH. Glenn HuddlestonDana IngramMr. and Mrs. David L. JohnsonKathryn and Bill JohnsonAnne W. JohnstonJanet Anabelle JonesLaurie and Michael J. KaplanKehl Motor ServiceBetty and Bob KelsoMr. and Mrs. Edward K. KopplowBonnie and John KorbellMr. and Mrs. Michael L. KreagerBarbara C. KyseCarolyn and Joe LabattJudith R. LachmanBill N. Lacy

Sarah and Milton LeeMr. and Mrs. Fred C. Lepick, Jr.Peggy and Jack LewisNancy Ann B. LoefflerDr. and Mrs. Michael Grant MacNaughtonMalitz Construction, Inc.Mike A. ManuppelliJaney Briscoe MarmionMr. and Mrs. W. W. McAllister, IIIDr. and Mrs. Michael S. McArthurCharline and Red McCombsJennifer and Joe McKinneySherry and Laird McNeilYona and Tom McNishJudy and Palmer MoeJulie and Balous MillerDr. and Mrs. Joseph P. MillerJohn C. MitchellJennifer and Kevin MoriartyTerrie and Jamie MusselmanMr. and Mrs. Frank R. NewtonPhil NormanMr. and Mrs. Mark MeadorMargie and Sam O’KrentSue OppenheimerSheri and Manny OrtizJudy and Seymour PalansDiane and Phil PfeifferAmelie and David RamirezJudy and Spencer ReddingKatie and Jim ReedHelen and Arthur RiklinAndrea F. RodriguezJill and Bobby RosenthalNancy B. RotherDianna and Drew RoyMr. and Mrs. Ronald RushingEduardo SalidoJane and Jimmy SatelMr. and Mrs. William Scanlan, Jr.Scantland Charitable FoundationMr. and Mrs. Richard T. Schlosberg, IIIThe Kyle and Billie Seale Family FoundationLisa and Kelly SechlerMitchel Kaliff and Bruce Smiley-KaliffJon H. Smith

Mr. and Mrs. Stanley SpigelAnna and Dennis StahlLynn and Sam StahlMr. and Mrs. Thomas A. StephensonFrancie and Harris SterlingPatricia G. StevesMr. and Mrs. Julian C. StewartJoci and Joe StrausRuth Eilene SullivanDrs. Donna and Ian Thompson, Jr.Nancy and Vernon TorgersonTriple Dawson Family FoundationCathy Raba TurcotteSuzanne and Dick WadeCourtney and Mark E. Watson, Jr.AnaPaula and Mark Watson, IIILora and Jim WattsGeoffrey and Martha WeissRene and Marty WenderLinda and Ed WhitacreBarbara and George WilliamsMr. and Mrs. Kenneth WilsonWong Family Enterprises Ltd.Mertie and Dale WoodBarbara WulfeMr. and Mrs. Carl E. WulfeDr. and Mrs. James William YancyDon and Wanda York

2015 SAN ANTONIO BREAST CANCER SYMPOSIUM SPONSORS

Premier ($200,000 +) Lilly Oncology Genentech

Angel ($125,000 +)AbbvieAstraZenecaGenomic HealthNovartis Oncology Pfizer Oncology

Patron ($80,000 +)Celgene CorporationEisai

COMMUNITY LEADERSHIP AND SUPPORT YEAR IN REVIEW YEAR IN REVIEW


Major Supporter ($50,000 +)Alphamed PressAmgenbioTheranosticsMedivation, Inc Myriad Genetic Laboratories, Inc.SandozTESARO

Contributers ($25,000 +)Agendia, Inc.Dune Medical ServicesNanoString TechnologiesNuclea Biotechnologies, Inc.Quest DiagnosticsR-Pharm US Teva Oncology

Donors ($10,000 +)Anonymous DonorAtossa GeneticsBioMed CentralCaris Life SciencesCelldex TherapeuticsClinical Oncology NewsCounsylDignitana AB Genentech GenPath Guardant HealthImpediMed, IncIntact Medical Corporation Integrated Oncology InvitaeMemorial Healthcare System Merck & Co., Inc.Miraca Life SciencesMolecular HealthNantomicsNewLink GeneticsPaxman Coolers, Ltd.Personal Genome DiagnosticsProvista DiagnosticsRareCyte, IncSanarus Technologies, Inc.Silicon BiosystemsSpectrum Pharmaceuticals, Inc.

Sysmex InosticsXcision Medical Systems, LLCXoft, a subsidiary of Icad, Inc

Special ThanksAvon FoundationSusan G. Komen Foundation

SAN ANTONIO EXPRESS-NEWS BOOK & AUTHOR LUNCHEON UNDERWRITERS (CASH GIFTS)

Nobel Laureate ($25,000 +)Mays Family FoundationSan Antonio Express-NewsValero Energy Foundation

Pulitzer ($10,000 +)AT&TKlesse FoundationSilver Eagle DistributorsUSAA Foundation

Best Sellers ($5,000 +)Argo Group USFrost BankH-E-BKaren and Tim HixonNancy and Ed KelleyThe Tobin Endowment

Program Design Sponsor ($5,000 +)Causality Studios

First Editions ($2,500 +)Ancira EnterprisesArgyle FoundationDavis, Cedillo & Mendoza, Inc.The Gorman FoundationHelen GrovesC.H. Guenther & Sons, Inc.IBC BankJulian Gold, Inc.Bonnie and John KorbellLangley & Banack, Incorporated

San Antonio Spurs, LLCLori and Mark WrightZachry Corporation

Classics ($1,500+)Bank of San AntonioBroadway BankPam and Art BurdickNancy and Charlie CheeverCITIErnst & Young LLPNorton, Rose, and FulbrightPizza Hut of San AntonioNancy and Vernon TorgersonDrs. Donna and Ian ThompsonUniversity of the Incarnate Word - Office of the President

Special ThanksAndi and BarbaraBig’z Burger JointJanet Holliday and the CE GroupDr. Coleen GrissomKalani YogurtThe Prestigious MarkScobey Moving and StorageSmokie Moe’s BBQTrinity PressThe Twig Book Shop

SAN ANTONIO EXPRESS-NEWS BOOK & AUTHOR LUNCHEON PROGRAM ADVERTISERS

Akin, Dougherty, Klein & Feuge PCAndie and Barbara Beckwith Electronic Engineering CoBjorn’s Audio VisualBlood and Tissue Foundation/ Mary and Steve Brook Joseph and Marjorie BrakeMary Ballenger BrookBudget MoversBurdick Custom Homes

Pam BurdickCancer Therapy & Research CenterCavender Auto GroupChamber Orchestra of San AntonioCheever BooksLisa CohickJudy Dalrymple DOCUmationDr. Rogers Weight Loss Center Ecumenical CenterElizabeth McCrae, MDEva’s HerosJudith EzraElizabeth FoxFralo’s PizzaCathy FriesePat FrostGrey Moss InnColeen Grissom, PhDLisa GroveGurinskys Fine JewelryInside Outside Wellness CenterCTRC’s Institute for Drug DevelopmentInterior EdgeJohn-William InteriorsLee Dental CentersLeon Springs Family DentalLighting IncMargie MoselyBeverley McClureMcNay Art MuseumMichael Imbimbo Inc ArchitectsModa BeBe Children’s BoutiqueJan NewtonNorth Park Lexus of San AntonioO’Krent’s FlooringPaula MarshPearl BreweryReznikov’s Fine JewelryRK Group / Catering by RosemaryDianna RoySan Antonio Portfolio Real Estate Schultz Landscaping & Design SPS DesignsSSFCUStudio One



Texas Treasures The Law Offices of Robert Cowan, Jr.The UPS StoreThyroid and Endocrine Center of South TexasTrinity University Trinity University PressVeltman and AssociatesVirtuoso BuildersWortham InsuranceArlene Wueste

VULCAN MATERIALS COMPANY GOLF TOURNAMENT SPONSORS

Platinum Team Sponsors ($5,000 +)Alonzo Cantu / Lone Star National BankValero Energy Corporation

Gold Team Sponsors ($2,500 +)Alamo CementAustin Powder CompanyBuckley Powder CompanyCapitol Aggregates, Inc.Clark ConstructionGreat Northwest ConcreteHunter IndustriesLone Star PavingMesa Equipment Co.Rush Truck Center San AntonioTurnkey Processing SolutionsUrban Concrete

Silver Sponsors ($1,500 +)Anthony MachineCEMEX Materials LLCDr. Ian M. Thompson, Jr.Future Concrete StructuresGencor IndustriesH.A. Kuehlem Survey CompanyHaynes and BooneHolt CatMidstate Environmental Services. LPMorlandt Electric Company

San Antonio Armature Works, Inc.Serenity Ranch / Tom RansdellShell AsphaltSika CorporationTCI Tire Centers, LLCWaukesha-Pearce Industries, Inc.

Individual Team ($1,000 +)8T1 ConstructionAggregate HaulersBirnbaum Property CompanyBurlington Northern Santa Fe RailwayBoral Material Technologies, Inc.Buckley Powder CompanyCarma ConstructionClement Industries/Utility Trailer of SE TXCMIContinental ContiTechDoggett Freightliner of South TexasElms, Harmon, MacchiaFly Ash DirectGCR Tire CentersGrey Forest UtilitiesWR Grace ConstructionJebro, Inc.Keystone Concrete PlacementK-Train TruckingPC ConcretePlant FabricatorsPrecision Ready MixProline MaintenanceRamming Paving Inc.Superior IndustriesTexas Lehigh CementUnico Cattle CompanyWinco Contractors

Closest to the Pin, Longest Drive and Hole Sponsors ($400+)CL Dews and Sons FoundryLee TranServicesMcNeilus Truck & ManufacturingTerracon Consultants, Inc.

WR Grace ConstructionCommunity Tire RetreadingErgon Asphalt & Emulsion, Inc.Hydraulic Supply and ServiceMcNeilus Truck & Manufacturing

Individual ($300+)Lee HullmanRodney OwensChris VestalMark Wright

Cash and Prize DonationsAlamo CaféBanners PlusBayne MineralsJohn BergerMike BessBridgestoneCDWCL Dews and Sons FoundryCommunity Tire RetreadingContinental ContiTechDoubletree HotelEl Tropicana HotelErgon Asphalt & Emulsion, Inc.GCR Tire CentersHerbst and AssociatesHilton Airport HotelHydraulic Supply and ServiceJebro Inc.JW Marriott ResortPat KerryLee TranServicesMcNeilus Truck & ManufacturingMesa EquipmentMidstate EnvironmentalPerico’s Mexican RestaurantShiner BeersStarcoTerraconTop GolfTPC San AntonioWR Grace Construction

BEQUESTS

Gwen and James CowdenDr. Bennett Dyke

ESTATE GIFTS

Jay L. AdelmanJerry O. CraftWalter L. GlotfeltyJohn J. KoppJoan PytelPearl G. Reaves

JESSE H. AND SUSAN R. OPPENHEIMER FELLOWSHIP IN NEW ANTICANCER DRUG DEVELOPMENT

The Jesse H. & Susan Oppenheimer Foundation / Sue Oppenheimer

KAREN AND RONALD HERRMANN BLADDER CANCER PROGRAM FUNDMr. and Mrs. J. Scott BeckendorfMr. and Mrs. Mark J. BerridgeAustin A. HerrmannMr. and Mrs. David S. HerrmannCarol H. MoreyEmilie H. Petty

WALTER LANG GLOTFELTY MEMORIAL RESEARCH FUND

Dr. and Mrs. John Robert BeauchampMr. Bob BecknerMr. and Mrs. C.L. BecknerMrs. Patricia CrainMr. and Mrs. Lukin T. GillilandGreater Houston Community FoundationMs. DeAnna HesterMr. and Mrs. William L KopplinMs. Toni OndekMr. and Ms. Brock G. PeacockMr. and Mrs. Robert P. PhippsThe Honorable Bonnie Reed and Mr. Stuart SchlossbergSCORE



Silver Eagle Distributors Charitable FundMr. Jack D. TrawickMrs. Rebekah WehmeyerMrs. Mary WoffordMr. and Mrs. Mark R. Wolf

FOUNDATION GRANTS

Anonymous DonorThe Leukemia & Lymphoma SocietySusan G. Komen for the Cure San Antonio

BRAIN CANCER RESEARCH

Gifts ($5,000 +)Mrs. June Marie DayMrs. Judith G. Roberson

Gifts (Under $1,000)Mrs. Kendra AbbottMr. and Mrs. Mark BernardMr. and Mrs. Rick BodleMs. Charlotte A. BrownMs. Bettie G. BurtonMrs. Sharon ClanceyMs. Suzanne K. CobbMr. and Mrs. Joe A. CrutchfieldMr. and Mrs. Ronald DennyMr. and Mrs. John DonnerMr. Richard EdwardsMs. Serita J. EdwardsElectro Communication Systems Inc.Mrs. Connie GaunttGivalikeMs. Regina GoldsteinDr. Coleen GrissomDr. William Mark HamiltonLeafGuard by Beldon, Inc.Mrs. Judith MinsonMr. and Mrs. William MoczygembaMrs. Stacey MorenoMr. and Mrs. Frank R. NewtonMr. and Mrs. Brad Ramsey

Mrs. Linda SheridanMr. and Mrs. Ben Smith, IIIMr. and Mrs. Richard B. StephensThe Rosenblatt Law FirmMrs. Katherine VargasMrs. Isidra VargasMrs. Roberta WiegmannMs. Marilyn S. Wright

BREAST CANCER RESEARCH AND TREATMENT

Gifts ($15,000 +)H-E-BSaks Fifth Avenue

Gifts ($10,000 +)Mrs. June Marie Day

Gifts ($2,000 +)Mrs. Karen Salsman

Gifts (Under $1,000)Ms. Michelle BerridgeMr. and Ms. Steven R. BrookDr. Elizabeth D. ConklynCorporate Travel Planners, Inc.Dr. and Mrs. Alex A. DePeraltaDr. Robert Luedecke and Ms. Anne FosterMr. and Mrs. William J. GoetzMr. and Mrs. Michael C. GrossMs. Lisa D. GroveMr. and Mrs. Charles H. GurinskyMr. and Mrs. Mario A. HernandezMr. and Mrs. Ronald HerrmannMr. and Mrs. Michael J. KaplanMr. and Mrs. Robert L. McDowellMotor Transport Post 1533 VFWMr. and Mrs. Walter MuslinMr. and Mrs. Sam O’KrentMs. Lynley Serratt

CANCER RESEARCH

Gifts ($75,000 +)CTRC CouncilTexas State Aerie, Fraternal Order of Eagles

Gifts ($50,000 +)Amy Shelton McNutt Charitable Trust

Gifts ($10,000 +)City of SchertzMr. and Mrs. Stanley D. Rosenberg

Gifts ($5,000 +)J.C. Heyser & Irene H. Heyser Memorial Fund

Gifts ($1,000 +)Mr. Chris CheeverGreen Courte Partners, LLCStar Parking/Corporate OfficesAmerican Legion Bicentennial Post 579 and AuxiliarySWBCMr. and Mrs. Carl E. Wulfe

Gifts (Under $1,000)Mr. and Mrs. Brian P. BradyMr. and Mrs. William S. BrinkleyMr. and Mrs. Duane BunceMs. Nancy CasselberryMr. Darin N. DigbyMr. and Mrs. Gary Eli DouglasMr. and Mrs. Michael C. FisherMr. and Mrs. James D. GoudgeMr. and Mrs. John HancockMr. and Mrs. John T. HarveyMrs. Karen L. HeintzThe Doctors Diana Kyle Henderson and Patrick N. BrownMr. and Mrs. Robert E. KelsoMr. Bill McWhorterMr. and Mrs. Jeffrey Allen RochelleMrs. Iris S. RubinMr. and Mrs. Michael P. SchweitzerMrs. Ruth Eilene SullivanMr. and Mrs. Arthur G. Uhl, IIIDr. Mary M. Walsh and Mr. Timothy WalshDr. and Mrs. Kaye Evan WilkinsMr. and Mrs. Richard D. HenryMr. and Mrs. Billy D. Langley

CTRC DIRECTOR’S CRITICAL NEEDS FUND

Gifts ($50,000 +)Mr. and Mrs. Clifton W. CoonrodJessie Frances Neal Foundation, Inc.

Gifts ($30,000 +)Dew FoundationMr. and Mrs. Dale Walsh

Gifts ($20,000 +)The USAA Foundation, Inc.

Gifts ($10,000 +)Mr. Charles C. Butt

Gifts ($2,000 +)Davis, Cedillo & Mendoza, Inc.Ms. Patricia DevoreNetwork For GoodMrs. Rhonda PetersonTruistWells Fargo Community Support Campaign

Gifts ($1,000 +)Mr. and Mrs. James C. BrowningMr. and Mrs. Richard H. CavenderDr. and Mrs. Lynn M. MoakMs. Brenda PawlakMr. and Mrs. Stanley D. RosenbergMrs. Karen Salsman

Gifts (Under $1,000)Akin, Doherty, Klein & FeugeAlamo Aero ServicesMrs. Nena AllevatoMr. and Mrs. Stanley AltermanAmy Shelton McNutt Charitable TrustMr. Richard ArroyoMr. and Mrs. Richard N. Azar, IIDr. and Mrs. Walter Mathis BainMr. and Mrs. Howard BakerMrs. Clara L. BaningBank of America United Way CampaignMs. Ann BarberMr. and Mrs. James F. BeckBenevity Community Impact FundMr. and Mrs. Mark BernardMr. and Mrs. Thomas E. BigelowSMSGT James E. Birkner and Ms. Robyn E. Becak



Ms. Frieda M. BleeckBless Your Heart, LLCMr. Donald W. BoehmeBoeing Company Enployee Individual Giving ProgramMr. and Mrs. Ralph BradfordMs. Pat BrannenMr. and Mrs. Todd R. BraulickMr. and Mrs. Elliott BrayMrs. Barbara BrischettoMr. and Mrs. James L. BristerMr. and Mrs. Steve BriteMr. and Mrs. Steve & Jean S. BriteMr. and Mrs. Steve BrownMr. and Mrs. Robert B. BurkhardtMs. Melanie CallDr. Roxanne Carmichael-RosalesMr. Mark CarolinMrs. Betty ChandlerMr. and Mrs. Charles E. Cheever, Jr.Ms. Isabel ChristianChristian Cowan Builder, LLCMr. and Mrs. Darrell ChunnMs. Kathleen CobbMr. and Mrs. Buddy CockrellMr. and Mrs. Ray ColeMs. F. Ann CrabtreeColonel (Ret.) and Mrs. Kenneth E. CrowMr. and Mrs. Harold A. DavenportMs. Susan Kay DavidsonMr. and Mrs. Charles H. DavisMrs. Olive F. DavisMr. and Mrs. Jeffrey Rollins DavisMrs. Lesley DavisMr. Cameron DawleyMr. and Mrs. Philip P. DidomenicoMs. Kristine DoyleMr. and Mrs. Thomas DroughtMr. and Mrs. Gerald Z. Dubinski, Sr.Mr. and Mrs. James DuerrMr. and Mrs. A. Baker Duncan, IIIMs. Terrie DunnMs. Evelyn EastersonMrs. Mildred V. EhrenbergMr. Mark EichelbaumMrs. Patty ElliottMs. Ramona EnriquezMr. and Mrs. Cesar Esparza

Mrs. Sharron E. FarrisFirstgivingMrs. Betsy FlorenceMr. Arthur D. FosterMs. Mary Beth FournierDr. Ruth K. and Mr. William M. FowlerMr. William E. Fox, Jr.Mr. and Mrs. Tom C. FrostMr. and Mrs. Carlos GamezGE United Way CampaignMr. and Mrs. C. Michael GentryMs. Pamela L. GilbertMr. and Mrs. Lukin T. GillilandMs. Grace M. GilmoreMs. Shelley GirndtGivalikeMr. and Mrs. Carl R. GlennMs. Cecile H. GloierMs. Linda GloverMs. Ann M. GraefingMs. Terry E. GrayMr. and Mrs. Joe F. GuestMr. and Mrs. Jimmy E. GuillotMr. and Mrs. Robert E. GurwitzMs. Ann Brooke HaasMr. and Mrs. Bill R. HaddockMr. and Mrs. T. L. Hairston, IIIMs. Rebecca B. Hallock-WolffMr. and Mrs. Kent HamiltonMr. and Mrs. Donald B. HarrellHarris & Eliza Kempner FoundationHarris K. & Lois G. Oppenheimer FoundationMrs. Mary Teresa HattenMr. Robert J. HaydenMrs. Karen L. HeintzMr. and Mrs. Roger R. HemminghausMr. and Mrs. Bruce HendinMr. and Mrs. Peter J. Hennessey, IIIDr. and Mrs. William L. HenrichJack and Valerie Guenther FoundationMs. Vanessa JacobsMrs. Shirley C. JanecekSusan Seale Jarvis, JDJoe R. Straus, Sr. & Emilie F. Straus Charitable TrustMs. Margaret A. JonesMiss Xonia Mary Kargl

Mr. and Mrs. Edward B. KelleyMr. and Mrs. Richard KelleyMr. and Mrs. Patrick J. Kennedy, Sr.Mr. and Mrs. Thomas H. KernsKerrville Public Utility BoardDr. and Mrs. Richard G. Kibbey, IIIMr. and Mrs. Richard M. Kleberg, IIIMs. Sheila KnowlesMrs. Rita R. KoplanMr. Larry KvetonMrs. Judith R. LachmanMr. Bill N. LacyMr. and Mrs. Louis F. LaglederLamesa National BankDr. Alisa LaneMr. Stephen S. LangMr. and Mrs. Marshall LaVineLeafGuard by Beldon, Inc.Mr. and Mrs. Richard K. LePereMrs. Barbara C. LettunichLive Oak League of ArtsMrs. Jeanette M. LowellMr. and Mrs. Richard MannheimerMrs. Janey Briscoe MarmionMr. and Mrs. Gerald Reese MathisMs. Patricia MayaMays Family FoundationMr. Gerald McCartyDr. and Mrs. Joe Robert McFarlane, Jr.Mrs. Gerry Thornton McGarraughMr. and Mrs. Peyton McNeillDr. and Mrs. Thomas M. McNishMr. and Mrs. Percy J. MelanconMr. and Mrs. William J. MerrillMr. and Mrs. Michael MetMs. Jenna MetzMs. Amy MiersDr. Daniel MitchellMrs. Virginia Evers MohrMr. Albert C. Molter, Jr.Mr. and Mrs. Charles MonacoMs. Elaine MooreMr. and Mrs. Lewis Jefferson Moorman, IIIMs. Ruth I. Moorman and Mr. Robert J. McVeyMs. Maria Del Rosario MorenoMr. and Mrs. Frank S. MorrillMorrison & Foerster Foundation

Mr. and Mrs. Daniel MotaMr. Ronnie NipperMs. Evelyn NixMr. Michael O’BoyleMs. Marilyn M. O’HairMrs. Claire O. O’MalleyMr. and Mrs. Daniel A. OstosMr. Jeffery OwenMr. G. OzunaP & L EnterprisesMr. and Mrs. William A. Parker, Sr.Mr. and Mrs. Glenn PartlinMiss Cynthia PawelekMr. and Mrs. Richard M. Peacock, Sr.Mr. Steven PeacockMs. Sandy K. PenningtonMs. Terry Jo PhillipsMrs. Tracy PickeringMrs. Sharon B. PilletMrs. Audrey Dubitzky PosellMrs. Patti PowersMrs. Sherri PulliamMrs. Donia RankinRansleben, Sentefitt, Sedwick & Co., P.C.Ms. Ruby M. RaybornMr. and Mrs. George M. Richmond, Jr.Ms. Billie Lynn RichterMr. and Mrs. Jack RipsMrs. Debie RodriguezColonel William T. RogersonMrs. Alice M. RosensteinMr. John Tarrillion and Ms. Karin RowlandMr. and Mrs. Douglas R. SaathoffMr. and Mrs. John J. SalvadoreSan Antonio Medical FoundationMs. Samantha SanchezMs. Uttara M. SawantMr. and Mrs. Alex ScharlackMr. and Mrs. Steve SchindlerMs. Martha SchuhMr. and Mrs. David SchwarzScott Petty FoundationMr. and Mrs. Guy B. SeayMrs. Linda N. SeeligsonSENTEL - AFMISTBMr. Donald SherwoodMr. and Mrs. C.W. ShirleyMr. Glen C. Skaggs



Mr. and Mrs. James Burleson Smith, Jr.Mr. and Mrs. Moddie E. SmithDr. and Mrs. John C. Sparks, Sr.Mr. and Mrs. David R. SpeerDr. and Mrs. James M. StedmanMr. and Mrs. Mark R SteinMr. and Mrs. Ben G. Sweet, Jr.Ms. Lori SweteTetco Companies, LPThe Herrmann Family Charitable FoundationThe Watson FoundationMr. and Mrs. Maurice E. TheisMr. and Mrs. Joseph I. ThomasThe Doctors Ian and Donna ThompsonMr. and Mrs. Arthur A. Tolbert, Jr.Mr. and Mrs. Jeffrey TrainMr. and Mrs. Herbert E. TroutzMr. Don L. TschirhartMrs. Aurline TschirhartUnited Way of Central & Northeastern ConnecticutUnited Way of San Antonio and Bexar CountyUnited Way of the Capital RegionThe Doctors Randall and Marilyn VanoverDr. Stephanie WardMs. Catherine WeberMs. Elizabeth WicklenDr. and Mrs. Hugh L. WolffMr. and Mrs. Ronald D. WolffMr. and Mrs. Mark H. WrightMr. and Mrs. Henry Bartell Zachry, Jr.

GASTROINTESTINAL CANCER RESEARCH

Gifts ($7,500 +)Mr. and Mrs. Harry Nelson

Gifts ($1,000 +)Mr. and Brian MitchellMrs. Karen Salsman

Gifts (Under $1,000)Professor Anthony BedfordMs. Debra DragichMs. Janet GrojeanColonel (Ret.) and Mrs. William V. Hill, II

Mr. and Mrs. Glenn KirbyMotor Transport Post 1533 VFWMr. Bradley PerkinsMr. and Mrs. Charlie DoerrMr. and Mrs. Kent HamiltonLeafGuard by Beldon, Inc.

HEAD AND NECK CANCER RESEARCH

Gifts (Under $1,000)Mr. and Mrs. Ronald P. BrittMr. and Mrs. Robert B. BurkhardtMs. Karen BurnettMs. Lorrie M. CarpenterMs. Terrie DunnMr. and Mrs. Jerry W. MoulderSt. Mark - Evangelist CatholicThe Gordon Hartman Family FoundationDr. and Mrs. Carl John WagenerMs. Katherine WheelerLieutenant Colonel (Ret.) and Mrs. William John Zwartjes

HEMATOLOGICAL CANCER RESEARCH

Gifts (Under $1,000)Mrs. Ann Karpowicz

LUNG CANCER RESEARCH

Gifts (Under $1,000)Mr. Aubrey George and Ms. Linda Lopez-George

PATIENT ASSISTANCE FUND

Gifts ($75,000 +)CTRC Council

Gifts ($7,000 +)Citi Business ServicesThe Parker Foundation, Inc.

Gifts ($5,000 +)Minnie Stevens Piper FoundationSt. Luke’s Lutheran Health Ministries, Inc.

Gifts ($2,500 +)Genentech, Inc.Mr. Jon H. Smith

Gifts (Under $1,000)Mr. and Mrs. Spencer BraxtonMr. and Mrs. Richard J CavazosMs. Frances L. ChilekMr. and Mrs. Donald M. CohickCTRC Institue for Drug DevelopmentMs. Mary CuellarMr. Henry A. Daughtry, Jr.Ms. Allison DePaoliMr. and Mrs. Cesar P. DiazMr. Ron EntrekinMr. and Mrs. Edwin EspeyMs. Sharon G. FoggMr. and Mrs. Charles H. FreemanMs. Teri GreenMr. and Mrs. Frank A. HabaMr. and Mrs. Randall HarredDr. and Mrs. Floyd Wright HartsellMr. and Mrs. James L. Hayne, Sr.Mr. Tom HeffernanHerndon Plant OakleyMr. and Mrs. Aaron HerrethMr. and Mrs. Brian D. HevnerDr. and Mrs. Leslie David HillisMr. and Mrs. Bobby J. HinesMr. and Mrs. Dennis Carroll HollandMr. and Mrs. Lloyd HouseMr. and Mrs. Barry D. IrishMs. Emma JasikMs. Kady JasikMs. Sandra A. JasikMr. and Mrs. Jeffrey JostMs. Marilyn KatcsmorakMs. Betty M. KatcsmorakMr. David E. KehlMr. and Mrs. Jere Wayne KellyD. Frances KnightMr. and Ms. Jerry KosubMr. and Mrs. Jean Pierre LairMrs. Heather LarsonLeafGuard by Beldon, Inc.Dr. and Mrs. James Carlton LeeMr. and Mrs. Preston Littrell, Jr.Ms. Genevieve LopezMs. Bojana Rastko MamuzicMr. and Mrs. Joe Markosfeld

Mr. and Mrs. Kenneth A. McClureDr. and Mrs. Thomas M. McNishMr. Gerardo MedinaMr. and Mrs. Edward F. MihalskiMr. Vincent J. MonteMr. and Mrs. Frank S. MorrillMr. and Mrs. Loyd E. MorrisMs. Jennifer MoseleyMr. and Mrs. Frank R. NewtonSheri and Manny OrtizMr. and Mrs. Charles PalmerMr. and Mrs. Larry PersynPhyllis Browning CompanyMs. Annie M. PieniazekMr. Daniel RamosMs. Judy ReidenbachL. & D. RetzloffMs. Mary A. RichterMr. and Mrs. Sam RodriguezMs. Lisa K. RooksMr. and Mrs. John J. SalvadoreDr. and Mrs. John J. SenyszynMs. Barbara Joan ShearrerMr. and Mrs. Randy ShearrerMs. Mary ShearrerMr. and Mrs. Guy R. SmithDr. and Mrs. James M. StedmanMr. and Mrs. Jose S TrevinoMrs. Loretta M. TuckMs. Melinda S. UrionMr. and Mrs. James R. WattsDr. and Mrs. Steven D. WeitmanMr. and Mrs. Mark H. WrightDr. and Mrs. Craig Mathewson WrightDr. and Mrs. James William YancyMr. and Mrs. David Steves ZachryMs. Celia L. ZimmermanAnne Ownby

RADIATION ONCOLOGY

Gifts ($5,000 +)Mr. Al Bissmeyer

Gifts ($1,000 +)Dr. Join Y. Luh

Gifts (Under $1,000)Dr. and Mrs. John J. Senyszyn


7979 Wurzbach RoadSan Antonio, TX 78229

THE ONLY NCI-DESIGNATED CANCER CENTER IN SOUTH TEXAS.

Make a gift to the CTRC uthscsa.edu/patient-care/ctrc/donate

210-450-1000Follow us online at www.ctrc.net

New Twitter Icon

Facebook “f ” Logo CMYK / .ai Facebook “f ” Logo CMYK / .ai

http://www.uthscsa.edu/patient-care/ctrc/donate

http://www.uthscsa.edu/patient-care/ctrc?utm_source=ctrcnet&utm_medium=pageredirect&utm_campaign=ctrcnethomepage

cancer therapy & research center (ctrc) annual report 2015

Documents